BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut 2015;64:830-41. [PMID: 25681399 DOI: 10.1136/gutjnl-2014-306842] [Cited by in Crossref: 485] [Cited by in F6Publishing: 462] [Article Influence: 80.8] [Reference Citation Analysis]
Number Citing Articles
1 Crespo Yanguas S, Willebrords J, Maes M, da Silva TC, Veloso Alves Pereira I, Cogliati B, Zaidan Dagli ML, Vinken M. Connexins and pannexins in liver damage. EXCLI J 2016;15:177-86. [PMID: 27065778 DOI: 10.17179/excli2016-119] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
2 Teratani T, Tomita K, Suzuki T, Furuhashi H, Irie R, Nishikawa M, Yamamoto J, Hibi T, Miura S, Minamino T, Oike Y, Hokari R, Kanai T. Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis. J Clin Invest 2018;128:1581-96. [PMID: 29553485 DOI: 10.1172/JCI92863] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
3 He L, Hou X, Fan F, Wu H. Quercetin stimulates mitochondrial apoptosis dependent on activation of endoplasmic reticulum stress in hepatic stellate cells. Pharm Biol 2016;54:3237-43. [PMID: 27572285 DOI: 10.1080/13880209.2016.1223143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
4 Xu Q, Sheng L, Bao H, Chen X, Guo C, Li H, Ma X, Qiu D, Hua J. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2017;32:639-644. [PMID: 27505153 DOI: 10.1111/jgh.13508] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
5 Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2017;33:134-41. [PMID: 28346237 DOI: 10.1097/MOG.0000000000000356] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
6 Paish HL, Reed LH, Brown H, Bryan MC, Govaere O, Leslie J, Barksby BS, Garcia Macia M, Watson A, Xu X, Zaki MYW, Greaves L, Whitehall J, French J, White SA, Manas DM, Robinson SM, Spoletini G, Griffiths C, Mann DA, Borthwick LA, Drinnan MJ, Mann J, Oakley F. A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision-Cut Liver Slices. Hepatology 2019;70:1377-91. [PMID: 30963615 DOI: 10.1002/hep.30651] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
7 Xie LT, Yan CH, Zhao QY, He MN, Jiang TA. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. World J Gastroenterol 2018; 24(9): 957-970 [PMID: 29531460 DOI: 10.3748/wjg.v24.i9.957] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
8 曾志萍, 郭津生. 肝纤维化发生机制及治疗研究进展. 世界华人消化杂志 2017; 25(7): 569-575 [DOI: 10.11569/wcjd.v25.i7.569] [Reference Citation Analysis]
9 Lv F, Wu J, Miao D, An W, Wang Y. p16 deficiency promotes nonalcoholic steatohepatitis via regulation of hepatic oxidative stress. Biochemical and Biophysical Research Communications 2017;486:264-9. [DOI: 10.1016/j.bbrc.2017.03.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lu ZN, Niu WX, Zhang N, Ge MX, Bao YY, Ren Y, Guo XL, He HW. Pantoprazole ameliorates liver fibrosis and suppresses hepatic stellate cell activation in bile duct ligation rats by promoting YAP degradation. Acta Pharmacol Sin 2020;42:1808-20. [PMID: 34465912 DOI: 10.1038/s41401-021-00754-w] [Reference Citation Analysis]
11 Afsari A, Lee E, Shokrani B, Boortalary T, Sherif ZA, Nouraie M, Laiyemo AO, Alkhalloufi K, Brim H, Ashktorab H. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C. Dig Dis Sci 2017;62:2159-65. [PMID: 28612194 DOI: 10.1007/s10620-017-4626-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Weiskirchen R, Tacke F. Liver fibrosis: Which mechanisms matter? Clin Liver Dis (Hoboken) 2016;8:94-9. [PMID: 31041072 DOI: 10.1002/cld.581] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Jun JH, Park SY, Park S, Park HJ, Kim JY, Park GT, Bae SH, Kim JH, Kim GJ. Formyl Peptide Receptor 2 Alleviates Hepatic Fibrosis in Liver Cirrhosis by Vascular Remodeling. Int J Mol Sci 2021;22:2107. [PMID: 33672682 DOI: 10.3390/ijms22042107] [Reference Citation Analysis]
14 Yovchev MI, Lee EJ, Rodriguez-Silva W, Locker J, Oertel M. Biliary Obstruction Promotes Multilineage Differentiation of Hepatic Stem Cells. Hepatol Commun 2019;3:1137-50. [PMID: 31388633 DOI: 10.1002/hep4.1367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Li JF, Zheng SJ, Wang LL, Liu S, Ren F, Chen Y, Bai L, Liu M, Duan ZP. Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl‑2/Bax pathway. Mol Med Rep 2017;16:7355-60. [PMID: 28944894 DOI: 10.3892/mmr.2017.7580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
16 van der Helm D, Groenewoud A, de Jonge-Muller ESM, Barnhoorn MC, Schoonderwoerd MJA, Coenraad MJ, Hawinkels LJAC, Snaar-Jagalska BE, van Hoek B, Verspaget HW. Mesenchymal stromal cells prevent progression of liver fibrosis in a novel zebrafish embryo model. Sci Rep 2018;8:16005. [PMID: 30375438 DOI: 10.1038/s41598-018-34351-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Wan S, Luo F, Huang C, Liu C, Luo Q, Zhu X. Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways. Aging (Albany NY) 2020;12:10614-32. [PMID: 32496208 DOI: 10.18632/aging.103282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Xu LM, Liu P; Hepatology Committee of Chinese Association of Integrative Medicine, China. Guidelines for diagnosis and treatment of hepatic fibrosis with integrated traditional Chinese and Western medicine (2019 edition). J Integr Med 2020;18:203-13. [PMID: 32331978 DOI: 10.1016/j.joim.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kim DH, Lee EM, Do SH, Jeong DH, Jeong KS. Changes of the Cytoplasmic Proteome in Response to Alcoholic Hepatotoxicity in Rats. Int J Mol Sci 2015;16:18664-82. [PMID: 26266409 DOI: 10.3390/ijms160818664] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Luetkens JA, Klein S, Traeber F, Schmeel FC, Sprinkart AM, Kuetting DLR, Block W, Hittatiya K, Uschner FE, Schierwagen R, Gieseke J, Schild HH, Trebicka J, Kukuk GM. Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. Gut 2018;67:593-4. [DOI: 10.1136/gutjnl-2017-314561] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
21 Zhang Z, Yao Z, Zhao S, Shao J, Chen A, Zhang F, Zheng S. Interaction between autophagy and senescence is required for dihydroartemisinin to alleviate liver fibrosis. Cell Death Dis. 2017;8:e2886. [PMID: 28617435 DOI: 10.1038/cddis.2017.255] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 12.3] [Reference Citation Analysis]
22 Casas-Grajales S, Alvarez-Suarez D, Ramos-Tovar E, Dayana Buendía-Montaño L, Reyes-Gordillo K, Camacho J, Tsutsumi V, Lakshman MR, Muriel P. Stevioside inhibits experimental fibrosis by down-regulating profibrotic Smad pathways and blocking hepatic stellate cell activation. Basic Clin Pharmacol Toxicol 2019;124:670-80. [PMID: 30561898 DOI: 10.1111/bcpt.13194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Xu T, Pan L, Ge Y, Li P, Meng X, Huang C, Li J. TMEM88 mediates inflammatory cytokines secretion by regulating JNK/P38 and canonical Wnt/β-catenin signaling pathway in LX-2 cells. Inflammopharmacol 2018;26:1339-48. [DOI: 10.1007/s10787-017-0419-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
24 Luo L, Xu T, Wang P, Mao L, Xi C, Huang J, Zhang W. Expression of muscarinic acetylcholine receptors in hepatocytes from rat fibrotic liver. Experimental and Toxicologic Pathology 2017;69:73-81. [DOI: 10.1016/j.etp.2016.11.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
25 Qiao JB, Fan QQ, Zhang CL, Lee J, Byun J, Xing L, Gao XD, Oh YK, Jiang HL. Hyperbranched lipoid-based lipid nanoparticles for bidirectional regulation of collagen accumulation in liver fibrosis. J Control Release 2020;321:629-40. [PMID: 32135224 DOI: 10.1016/j.jconrel.2020.02.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
26 Ogawa H, Kaji K, Nishimura N, Takagi H, Ishida K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. J Cell Mol Med 2021;25:4001-13. [PMID: 33609067 DOI: 10.1111/jcmm.16363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jia Z, Gong Y, Pi Y, Liu X, Gao L, Kang L, Wang J, Yang F, Tang J, Lu W, Li Q, Zhang W, Yan Z, Yu L. pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis. Mol Pharm 2018;15:53-62. [PMID: 29148802 DOI: 10.1021/acs.molpharmaceut.7b00709] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
28 Dong B, Huang S, Chang J, Chen X, Yan J. Comparison of Sound Touch Elastography, Sound Touch Quantify, and 4 Serum Fibrosis Indexes for the Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B. Ultrasound Q 2021;37:123-8. [PMID: 34057912 DOI: 10.1097/RUQ.0000000000000485] [Reference Citation Analysis]
29 Jamhiri I, Zahri S, Mehrabani D, Khodabandeh Z, Dianatpour M, Yaghobi R, Hosseini SY. Enhancing the apoptotic effect of IL-24/mda-7 on the human hepatic stellate cell through RGD peptide modification. Immunological Investigations 2018;47:335-50. [DOI: 10.1080/08820139.2018.1433202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Mao X, Liu Z, Shi O, Yu K, Jiang Y, Jin L, Zhang T, Chen X. Non-invasive fibrosis markers are associated with mortality risk in both general populations and non-alcoholic fatty liver disease patients. Hepatol Res 2021;51:90-101. [PMID: 32946623 DOI: 10.1111/hepr.13570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:365-85. [PMID: 27063275 DOI: 10.1016/j.cld.2015.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
32 Santoro R, Mangia A. Progress in promising anti-fibrotic therapies. Expert Rev Gastroenterol Hepatol 2019;13:1145-52. [PMID: 31692390 DOI: 10.1080/17474124.2019.1688659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
33 Wei W, Jiang F, Liu XC, Su Q. TMEM9 mediates IL-6 and IL-1β secretion and is modulated by the Wnt pathway. Int Immunopharmacol 2018;63:253-60. [PMID: 30119033 DOI: 10.1016/j.intimp.2018.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
35 Chen F, Sheng L, Xu C, Li J, Ali I, Li H, Cai Y. Ufbp1, a Key Player of Ufm1 Conjugation System, Protects Against Ketosis-Induced Liver Injury via Suppressing Smad3 Activation. Front Cell Dev Biol 2021;9:676789. [PMID: 34307359 DOI: 10.3389/fcell.2021.676789] [Reference Citation Analysis]
36 Tian X, Zhao C, Guo J, Xie S, Yin F, Huo X, Zhang X. Carvedilol Attenuates the Progression of Hepatic Fibrosis Induced by Bile Duct Ligation. Biomed Res Int 2017;2017:4612769. [PMID: 28396867 DOI: 10.1155/2017/4612769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
37 Asada K, Kaji K, Sato S, Seki K, Shimozato N, Kawaratani H, Takaya H, Sawada Y, Nakanishi K, Furukawa M, Kitade M, Moriya K, Namisaki T, Noguchi R, Akahane T, Yoshiji H. Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2'-deoxycytidine in Hepatic Stellate Cells. Biology (Basel) 2020;9:E117. [PMID: 32503264 DOI: 10.3390/biology9060117] [Reference Citation Analysis]
38 Yamada N, Katano T, Hirata Y, Okada N, Sanada Y, Ihara Y, Urahashi T, Ushijima K, Karasawa T, Takahashi M, Mizuta K. Serum Mac-2 binding protein glycosylation isomer predicts the activation of hepatic stellate cells after liver transplantation: M2BPGi in liver transplant recipients. Journal of Gastroenterology and Hepatology 2019;34:418-24. [DOI: 10.1111/jgh.14438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
39 McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, Stocken DD, Steen N, Barnes J, Goudie N, Stewart S, Bury Y, Mann D, Anstee QM, Day CP. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One 2017;12:e0175717. [PMID: 28419124 DOI: 10.1371/journal.pone.0175717] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
40 Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, Richards T, Yoneyama H, Jenkins H, Wolfgang G, Friedman SL. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016;11:e0158156. [PMID: 27347680 DOI: 10.1371/journal.pone.0158156] [Cited by in Crossref: 160] [Cited by in F6Publishing: 150] [Article Influence: 32.0] [Reference Citation Analysis]
41 Cai S, Wu L, Yuan S, Liu G, Wang Y, Fang L, Xu D. Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway. Eur J Pharmacol 2021;898:173982. [PMID: 33647257 DOI: 10.1016/j.ejphar.2021.173982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lefebvre P, Lalloyer F, Baugé E, Pawlak M, Gheeraert C, Dehondt H, Vanhoutte J, Woitrain E, Hennuyer N, Mazuy C, Bobowski-Gérard M, Zummo FP, Derudas B, Driessen A, Hubens G, Vonghia L, Kwanten WJ, Michielsen P, Vanwolleghem T, Eeckhoute J, Verrijken A, Van Gaal L, Francque S, Staels B. Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. JCI Insight 2017;2:92264. [PMID: 28679947 DOI: 10.1172/jci.insight.92264] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
43 Gonzalez HC, Duarte-Rojo A. Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes. Curr Gastroenterol Rep 2016;18:32. [PMID: 27177638 DOI: 10.1007/s11894-016-0508-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
44 Zheng S, Chen Y, Zheng S, He Z, Weng Z. Inhibition of Mastermind-like 1 alleviates liver fibrosis induced by carbon tetrachloride in rats. Exp Biol Med (Maywood) 2018;243:1099-108. [PMID: 30400752 DOI: 10.1177/1535370218810892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Li W, Zhang J, Lv Y, Sheibani N. Quantitative proteomic study of arsenic treated mouse liver sinusoidal endothelial cells using a reverse super-SILAC method. Biochem Biophys Res Commun 2019;514:475-81. [PMID: 31056257 DOI: 10.1016/j.bbrc.2019.04.172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. J Hepatol. 2015;62:S15-24. [PMID: 25920084 DOI: 10.1016/j.jhep.2015.02.039] [Cited by in Crossref: 350] [Cited by in F6Publishing: 327] [Article Influence: 70.0] [Reference Citation Analysis]
47 Wu HM, Sheng L, Wang Q, Bao H, Miao Q, Xiao X, Guo CJ, Li H, Ma X, Qiu DK, Hua J. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome. World J Gastroenterol 2018; 24(6): 737-743 [PMID: 29456412 DOI: 10.3748/wjg.v24.i6.737] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
48 Cheng R, Xu H, Hong Y. miR221 regulates TGF-β1-induced HSC activation through inhibiting autophagy by directly targeting LAMP2. Mol Med Rep 2021;24:777. [PMID: 34498712 DOI: 10.3892/mmr.2021.12417] [Reference Citation Analysis]
49 Foglia B, Sutti S, Pedicini D, Cannito S, Bocca C, Maggiora M, Bevacqua MR, Rosso C, Bugianesi E, Albano E, Novo E, Parola M. Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. Cells 2019;9:E28. [PMID: 31861914 DOI: 10.3390/cells9010028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
50 Bauters D, Spincemaille P, Geys L, Cassiman D, Vermeersch P, Bedossa P, Scroyen I, Lijnen HR. ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity. Liver Int 2016;36:1848-59. [PMID: 27254774 DOI: 10.1111/liv.13181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
51 Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397-411. [PMID: 28487545 DOI: 10.1038/nrgastro.2017.38] [Cited by in Crossref: 770] [Cited by in F6Publishing: 736] [Article Influence: 192.5] [Reference Citation Analysis]
52 Cannito S, Novo E, Parola M. Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Adv Drug Deliv Rev 2017;121:57-84. [PMID: 28578015 DOI: 10.1016/j.addr.2017.05.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
53 Moscoso CG, Steer CJ. "Let my liver rather heat with wine" - a review of hepatic fibrosis pathophysiology and emerging therapeutics. Hepat Med 2019;11:109-29. [PMID: 31565001 DOI: 10.2147/HMER.S213397] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Yang D, Yao M, Yan Y, Liu Y, Wen X, Chen X, Lu F. Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease. Biomolecules 2021;11:205. [PMID: 33540642 DOI: 10.3390/biom11020205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
56 Liu F, Chen L, Rao HY, Teng X, Ren YY, Lu YQ, Zhang W, Wu N, Liu FF, Wei L. Automated evaluation of liver fibrosis in thioacetamide, carbon tetrachloride, and bile duct ligation rodent models using second-harmonic generation/two-photon excited fluorescence microscopy. Lab Invest. 2017;97:84-92. [PMID: 27918557 DOI: 10.1038/labinvest.2016.128] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
57 Su W, Tai Y, Tang SH, Ye YT, Zhao C, Gao JH, Tuo BG, Tang CW. Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats. World J Gastroenterol 2020; 26(28): 4094-4107 [PMID: 32821072 DOI: 10.3748/wjg.v26.i28.4094] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Pinato DJ, Dalla Pria A, Sharma R, Bower M. Hepatocellular carcinoma: an evolving challenge in viral hepatitis and HIV coinfection. AIDS 2017;31:603-11. [DOI: 10.1097/qad.0000000000001422] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
59 Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 16.3] [Reference Citation Analysis]
60 Wang K, Guo Z, Bao Y, Pang Y, Li Y, He H, Song D. Structure-Activity Relationship of Aloperine Derivatives as New Anti-Liver Fibrogenic Agents. Molecules 2020;25:E4977. [PMID: 33121156 DOI: 10.3390/molecules25214977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Wang H, Yin S. Natural killer T cells in liver injury, inflammation and cancer. Expert Rev Gastroenterol Hepatol 2015;9:1077-85. [PMID: 26068039 DOI: 10.1586/17474124.2015.1056738] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
62 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 971] [Article Influence: 188.2] [Reference Citation Analysis]
63 Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018;68:361-371. [PMID: 29222911 DOI: 10.1002/hep.29724] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 53.7] [Reference Citation Analysis]
64 Ramachandran P, Henderson NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges. The Lancet Gastroenterology & Hepatology 2016;1:328-40. [DOI: 10.1016/s2468-1253(16)30110-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
65 Abdelsameea E, Alsebaey A, Abdel-Samiee M, Abdel-Razek W, Salama M, Waked I. Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Rev Anti Infect Ther 2021;19:1053-9. [PMID: 33307880 DOI: 10.1080/14787210.2021.1864326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 de Oliveira da Silva B, Ramos LF, Moraes KCM. Molecular interplays in hepatic stellate cells: apoptosis, senescence, and phenotype reversion as cellular connections that modulate liver fibrosis. Cell Biol Int 2017;41:946-59. [PMID: 28498509 DOI: 10.1002/cbin.10790] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
67 Yang X, Ma L, Wei R, Ye T, Zhou J, Wen M, Men R, Aqeilan RI, Peng Y, Yang L. Twist1-induced miR-199a-3p promotes liver fibrosis by suppressing caveolin-2 and activating TGF-β pathway. Signal Transduct Target Ther 2020;5:75. [PMID: 32499481 DOI: 10.1038/s41392-020-0169-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
68 Ginès P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, Guha IN, Murad SD, Castera L. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology 2016;1:256-60. [DOI: 10.1016/s2468-1253(16)30081-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 18] [Article Influence: 12.2] [Reference Citation Analysis]
69 Gratte FD, Pasic S, Abu Bakar NDB, Gogoi-Tiwari J, Liu X, Carlessi R, Kisseleva T, Brenner DA, Ramm GA, Olynyk JK, Tirnitz-Parker JEE. Previous liver regeneration induces fibro-protective mechanisms during thioacetamide-induced chronic liver injury. Int J Biochem Cell Biol 2021;134:105933. [PMID: 33540107 DOI: 10.1016/j.biocel.2021.105933] [Reference Citation Analysis]
70 Yang A, Yan X, Xu H, Fan X, Zhang M, Huang T, Li W, Chen W, Jia J, You H. Selective depletion of hepatic stellate cells-specific LOXL1 alleviates liver fibrosis. FASEB J 2021;35:e21918. [PMID: 34569648 DOI: 10.1096/fj.202100374R] [Reference Citation Analysis]
71 McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int. 2018;12:11-23. [PMID: 29075990 DOI: 10.1007/s12072-017-9826-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
72 Ni M, Wang L, Yu H, Wen X, Yang Y, Liu G, Hu Y, Li Z. Radiomics Approaches for Predicting Liver Fibrosis With Nonenhanced T1 -Weighted Imaging: Comparison of Different Radiomics Models. J Magn Reson Imaging 2021;53:1080-9. [PMID: 33043991 DOI: 10.1002/jmri.27391] [Reference Citation Analysis]
73 Tee JK, Peng F, Tan YL, Yu B, Ho HK. Magnesium Isoglycyrrhizinate Ameliorates Fibrosis and Disrupts TGF-β-Mediated SMAD Pathway in Activated Hepatic Stellate Cell Line LX2. Front Pharmacol 2018;9:1018. [PMID: 30319402 DOI: 10.3389/fphar.2018.01018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
74 Wan S, Huang C, Wang A, Zhu X. Ursolic acid improves the bacterial community mapping of the intestinal tract in liver fibrosis mice. PeerJ 2020;8:e9050. [PMID: 32355580 DOI: 10.7717/peerj.9050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Tan S, Liu X, Chen L, Wu X, Tao L, Pan X, Tan S, Liu H, Jiang J, Wu B. Fas/FasL mediates NF-κBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis. Cell Death Dis 2021;12:474. [PMID: 33980818 DOI: 10.1038/s41419-021-03749-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Ding R, Zheng J, Li N, Cheng Q, Zhu M, Wang Y, Zhou X, Zhang Z, Shi G. DZNep, an inhibitor of the histone methyltransferase EZH2, suppresses hepatic fibrosis through regulating miR-199a-5p/SOCS7 pathway. PeerJ 2021;9:e11374. [PMID: 34040893 DOI: 10.7717/peerj.11374] [Reference Citation Analysis]
77 Liu HL, Lv J, Zhao ZM, Xiong AM, Tan Y, Glenn JS, Tao YY, Weng HL, Liu CH. Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. Sci Rep 2019;9:18719. [PMID: 31822697 DOI: 10.1038/s41598-019-54663-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
78 Li H, Ding P, Peng B, Ming YZ. Cross-talk between hepatic stellate cells and T lymphocytes in liver fibrosis. Hepatobiliary Pancreat Dis Int 2021;20:207-14. [PMID: 33972160 DOI: 10.1016/j.hbpd.2021.04.007] [Reference Citation Analysis]
79 Jonscher KR, Abrams J, Friedman JE. Maternal Diet Alters Trained Immunity in the Pathogenesis of Pediatric NAFLD. J Cell Immunol 2020;2:315-25. [PMID: 33426540 DOI: 10.33696/immunology.2.061] [Reference Citation Analysis]
80 Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, Irving W, Forrest E, Pedergnana V, Goldberg D, Aspinall E, Barclay S, Hayes PC, Dillon J, Nischalke HD, Lutz P, Spengler U, Fischer J, Berg T, Brosch M, Eyer F, Datz C, Mueller S, Peccerella T, Deltenre P, Marot A, Soyka M, McQuillin A, Morgan MY, Hampe J, Stickel F. Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology 2020;159:1276-1289.e7. [PMID: 32561361 DOI: 10.1053/j.gastro.2020.06.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
81 Zeng Z, Wu Y, Cao Y, Yuan Z, Zhang Y, Zhang DY, Hasegawa D, Friedman SL, Guo J. Slit2-Robo2 signaling modulates the fibrogenic activity and migration of hepatic stellate cells. Life Sci 2018;203:39-47. [PMID: 29660433 DOI: 10.1016/j.lfs.2018.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
82 Goldberg DJ, Surrey LF, Glatz AC, Dodds K, O'Byrne ML, Lin HC, Fogel M, Rome JJ, Rand EB, Russo P, Rychik J. Hepatic Fibrosis Is Universal Following Fontan Operation, and Severity is Associated With Time From Surgery: A Liver Biopsy and Hemodynamic Study. J Am Heart Assoc 2017;6:e004809. [PMID: 28446492 DOI: 10.1161/JAHA.116.004809] [Cited by in Crossref: 105] [Cited by in F6Publishing: 26] [Article Influence: 26.3] [Reference Citation Analysis]
83 Scheiber IF, Brůha R, Dušek P. Pathogenesis of Wilson disease. Handb Clin Neurol 2017;142:43-55. [PMID: 28433109 DOI: 10.1016/B978-0-444-63625-6.00005-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
84 Bian Z, Miao Q, Zhong W, Zhang H, Wang Q, Peng Y, Chen X, Guo C, Shen L, Yang F, Xu J, Qiu D, Fang J, Friedman S, Tang R, Gershwin ME, Ma X. Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. J Autoimmun 2015;63:76-87. [PMID: 26238209 DOI: 10.1016/j.jaut.2015.07.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
85 Zhang F, Lu C, Xu W, Shao J, Wu L, Lu Y, Zheng S. Curcumin raises lipid content by Wnt pathway in hepatic stellate cell. J Surg Res 2016;200:460-6. [PMID: 26414021 DOI: 10.1016/j.jss.2015.08.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
86 Jones H, Hargrove L, Kennedy L, Meng F, Graf-Eaton A, Owens J, Alpini G, Johnson C, Bernuzzi F, Demieville J, DeMorrow S, Invernizzi P, Francis H. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice. Hepatology 2016;64:1202-16. [PMID: 27351144 DOI: 10.1002/hep.28704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
87 Hernández A, Arab JP, Reyes D, Lapitz A, Moshage H, Bañales JM, Arrese M. Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy. Cells 2020;9:E817. [PMID: 32231001 DOI: 10.3390/cells9040817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
88 Ma X, Tang M, Lu L, Zheng J, Huang J, Li J, Luo W. Effects of salvianolic acid B on liver fibrosis: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2020;99:e21036. [PMID: 32664111 DOI: 10.1097/MD.0000000000021036] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Zhang H, Ju B, Nie Y, Song B, Xu Y, Gao P. Adenovirus‑mediated knockdown of activin A receptor type 2A attenuates immune‑induced hepatic fibrosis in mice and inhibits interleukin‑17‑induced activation of primary hepatic stellate cells. Int J Mol Med 2018;42:279-89. [PMID: 29620144 DOI: 10.3892/ijmm.2018.3600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
90 Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. [PMID: 30213667 DOI: 10.1016/j.mam.2018.09.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 121] [Article Influence: 40.3] [Reference Citation Analysis]
91 Panera N, Meroni M, Longo M, Crudele A, Valenti L, Bellacchio E, Miele L, D'Oria V, Paolini E, Maggioni M, Fracanzani AL, Alisi A, Dongiovanni P. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine 2021;65:103249. [PMID: 33640795 DOI: 10.1016/j.ebiom.2021.103249] [Reference Citation Analysis]
92 Iwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clin Mol Hepatol. 2015;21:319-325. [PMID: 26770919 DOI: 10.3350/cmh.2015.21.4.319] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
93 Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol 2019; 25(2): 163-177 [PMID: 30670907 DOI: 10.3748/wjg.v25.i2.163] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 25.0] [Reference Citation Analysis]
94 Kapoor N, Audsley J, Rupali P, Sasadeusz J, Paul TV, Thomas N, Lewin SR. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS 2019;33:1105-15. [PMID: 31045941 DOI: 10.1097/QAD.0000000000002161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
95 Hu C, Wu Z, Li L. Mesenchymal stromal cells promote liver regeneration through regulation of immune cells. Int J Biol Sci. 2020;16:893-903. [PMID: 32071558 DOI: 10.7150/ijbs.39725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
96 Hou C, Wang D, Li X, He Y, Wei C, Jiang R, Liu J, Feng L, Shen Y. MANF regulates splenic macrophage differentiation in mice. Immunol Lett. 2019;212:37-45. [PMID: 31226359 DOI: 10.1016/j.imlet.2019.06.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
97 Drinane MC, Yaqoob U, Yu H, Luo F, Greuter T, Arab JP, Kostallari E, Verma VK, Maiers J, De Assuncao TM, Simons M, Mukhopadhyay D, Kisseleva T, Brenner DA, Urrutia R, Lomberk G, Gao Y, Ligresti G, Tschumperlin DJ, Revzin A, Cao S, Shah VH. Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI Insight 2017;2:92821. [PMID: 29263300 DOI: 10.1172/jci.insight.92821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
98 Lambrecht J, van Grunsven LA, Tacke F. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother 2020;21:1637-50. [PMID: 32543284 DOI: 10.1080/14656566.2020.1774553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
99 Sun X, Tan Y, Lyu J, Liu HL, Zhao ZM, Liu CH. Active Components Formulation Developed from Fuzheng Huayu Recipe () for Anti-Liver Fibrosis. Chin J Integr Med 2021. [PMID: 34581939 DOI: 10.1007/s11655-021-3293-x] [Reference Citation Analysis]
100 Guo T, Liu ZL, Zhao Q, Zhao ZM, Liu CH. A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo. Acta Pharmacol Sin 2018;39:1483-92. [PMID: 29849130 DOI: 10.1038/aps.2017.175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
101 Sommer J, Dorn C, Gäbele E, Bataille F, Freese K, Seitz T, Thasler WE, Büttner R, Weiskirchen R, Bosserhoff A, Hellerbrand C. Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury. Cells 2020;9:E248. [PMID: 31963815 DOI: 10.3390/cells9010248] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Manka P, Bechmann L, Best J, Sydor S, Claridge LC, Coombes JD, Canbay A, Moeller L, Gerken G, Wedemeyer H, Syn WK. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. Dig Dis Sci 2019;64:2351-8. [PMID: 31155687 DOI: 10.1007/s10620-019-05687-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
103 Ghazal K, Morales O, Barjon C, Dahlqvist G, Aoudjehane L, Ouaguia L, Delhem N, Conti F. Early high levels of regulatory T cells and T helper 1 may predict the progression of recurrent hepatitis C after liver transplantation. Clin Res Hepatol Gastroenterol 2019;43:273-81. [PMID: 30713032 DOI: 10.1016/j.clinre.2018.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Hargrove L, Kennedy L, Demieville J, Jones H, Meng F, DeMorrow S, Karstens W, Madeka T, Greene J Jr, Francis H. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient KitW-sh mice. Hepatology 2017;65:1991-2004. [PMID: 28120369 DOI: 10.1002/hep.29079] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
105 Chen L, Brenner DA, Kisseleva T. Combatting Fibrosis: Exosome-Based Therapies in the Regression of Liver Fibrosis. Hepatol Commun. 2018;3:180-192. [PMID: 30766956 DOI: 10.1002/hep4.1290] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
106 Hong Y, Yao Q, Zheng L. Thymosin β4 attenuates liver fibrosis via suppressing Notch signaling. Biochem Biophys Res Commun 2017;493:1396-401. [PMID: 28965947 DOI: 10.1016/j.bbrc.2017.09.156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
107 Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:105-114. [PMID: 26157746 DOI: 10.3350/cmh.2015.21.2.105] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 13.3] [Reference Citation Analysis]
108 Hellerbrand C, Massoumi R. Cylindromatosis-A Protective Molecule against Liver Diseases: CYLD IN LIVER DISEASE. Med Res Rev 2016;36:342-59. [DOI: 10.1002/med.21381] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
109 Luo N, Li J, Chen Y, Xu Y, Wei Y, Lu J, Dong R. Hepatic stellate cell reprogramming via exosome-mediated CRISPR/dCas9-VP64 delivery. Drug Deliv 2021;28:10-8. [PMID: 33336604 DOI: 10.1080/10717544.2020.1850917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
110 Nobili V, Miele L, Alisi A. Preventing liver fibrosis in patients with NAFLD and the road ahead. Expert Review of Gastroenterology & Hepatology 2017;11:1081-3. [DOI: 10.1080/17474124.2017.1389276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 Fagone P, Mangano K, Pesce A, Portale TR, Puleo S, Nicoletti F. Emerging therapeutic targets for the treatment of hepatic fibrosis. Drug Discovery Today 2016;21:369-75. [DOI: 10.1016/j.drudis.2015.10.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
112 Shi C, Yang H, Zhang Z. Involvement of Nucleotide-Binding Oligomerization Domain-Like Receptor Family Pyrin Domain Containing 3 Inflammasome in the Pathogenesis of Liver Diseases. Front Cell Dev Biol 2020;8:139. [PMID: 32211410 DOI: 10.3389/fcell.2020.00139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
113 Ramos-Tovar E, Muriel P. Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver. Antioxidants (Basel) 2020;9:E1279. [PMID: 33333846 DOI: 10.3390/antiox9121279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
114 Nie Y, Liu Q, Zhang W, Wan Y, Huang C, Zhu X. Ursolic acid reverses liver fibrosis by inhibiting NOX4/NLRP3 inflammasome pathways and bacterial dysbiosis. Gut Microbes 2021;13:1972746. [PMID: 34530693 DOI: 10.1080/19490976.2021.1972746] [Reference Citation Analysis]
115 Cinar R, Iyer MR, Liu Z, Cao Z, Jourdan T, Erdelyi K, Godlewski G, Szanda G, Liu J, Park JK, Mukhopadhyay B, Rosenberg AZ, Liow JS, Lorenz RG, Pacher P, Innis RB, Kunos G. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight 2016;1:87336. [PMID: 27525312 DOI: 10.1172/jci.insight.87336] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
116 Zhu X, Ye S, Yu D, Zhang Y, Li J, Zhang M, Leng Y, Yang T, Luo J, Chen X, Zhang H, Kong L. Physalin B attenuates liver fibrosis via suppressing LAP2α-HDAC1-mediated deacetylation of the transcription factor GLI1 and hepatic stellate cell activation. Br J Pharmacol 2021;178:3428-47. [PMID: 33864382 DOI: 10.1111/bph.15490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
117 Dawood RM, El-meguid MA, Salum GM, El Awady MK. Key Players of Hepatic Fibrosis. Journal of Interferon & Cytokine Research 2020;40:472-89. [DOI: 10.1089/jir.2020.0059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
118 Wang HY, Li C, Liu WH, Deng FM, Ma Y, Guo LN, Kong H, Hu KA, Liu Q, Wu J, Sun J, Liu YL. Autophagy inhibition via Becn1 downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis. J Cell Physiol. 2020;235:2722-2737. [PMID: 31508820 DOI: 10.1002/jcp.29176] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
119 Nah EH, Cho S, Kim S, Chu J, Kwon E, Cho HI. Prevalence of liver fibrosis and associated risk factors in the Korean general population: a retrospective cross-sectional study. BMJ Open 2021;11:e046529. [PMID: 33762246 DOI: 10.1136/bmjopen-2020-046529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Rudraiah S, Zhang X, Wang L. Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? Annu Rev Pharmacol Toxicol. 2016;56:605-626. [PMID: 26738480 DOI: 10.1146/annurev-pharmtox-010715-103209] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
121 Athwal VS, Pritchett J, Llewellyn J, Martin K, Camacho E, Raza SM, Phythian-Adams A, Birchall LJ, Mullan AF, Su K, Pearmain L, Dolman G, Zaitoun AM, Friedman SL, MacDonald A, Irving WL, Guha IN, Hanley NA, Piper Hanley K. SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis. EMBO Mol Med 2017;9:1696-710. [PMID: 29109128 DOI: 10.15252/emmm.201707860] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
122 Yang H, Xie Y, Li T, Liu S, Zeng S, Wang B. A novel minimally invasive OFM technique with orthotopic transplantation of hUC-MSCs and in vivo monitoring of liver metabolic microenvironment in liver fibrosis treatment. Stem Cell Res Ther 2021;12:534. [PMID: 34627378 DOI: 10.1186/s13287-021-02599-w] [Reference Citation Analysis]
123 Bai L, Liu X, Zheng Q, Kong M, Zhang X, Hu R, Lou J, Ren F, Chen Y, Zheng S, Liu S, Han YP, Duan Z, Pandol SJ. M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes. Sci Rep 2017;7:10518. [PMID: 28874845 DOI: 10.1038/s41598-017-11303-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
124 Guo YC, Lu LG. Antihepatic Fibrosis Drugs in Clinical Trials. J Clin Transl Hepatol 2020;8:304-12. [PMID: 33083254 DOI: 10.14218/JCTH.2020.00023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
125 Mansy SS, Nosseir MM, Othman MM, Zoheiry MA, Guda MF, Yehia HA, Hassanein MH. Spotlight on the three main hepatic fibrogenic cells in HCV-infected patients: Multiple immunofluorescence and ultrastructure study. Ultrastructural Pathology 2016;40:276-87. [DOI: 10.1080/01913123.2016.1194507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
126 Yang JH, Kim KM, Cho SS, Shin SM, Ka SO, Na CS, Park BH, Jegal KH, Kim JK, Ku SK, Lee HJ, Park SG, Cho IJ, Ki SH. Inhibitory Effect of Sestrin 2 on Hepatic Stellate Cell Activation and Liver Fibrosis. Antioxid Redox Signal 2019;31:243-59. [PMID: 30909713 DOI: 10.1089/ars.2018.7559] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
127 Rieder F, Bettenworth D, Imai J, Inagaki Y. Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology? Inflamm Intest Dis. 2016;1:41-49. [PMID: 29922656 DOI: 10.1159/000445135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
128 Jiang M, Wu Y, Li X, Zhang Y, Xia K, Cui B, Lian L, Nan J. Oligomeric proanthocyanidin derived from grape seeds inhibited NF-κB signaling in activated HSC: Involvement of JNK/ERK MAPK and PI3K/Akt pathways. Biomedicine & Pharmacotherapy 2017;93:674-80. [DOI: 10.1016/j.biopha.2017.06.105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
129 Gerarduzzi C, Di Battista JA. Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective. Inflamm Res. 2017;66:451-465. [PMID: 28040859 DOI: 10.1007/s00011-016-1019-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
130 Yang X, Dan X, Men R, Ma L, Wen M, Peng Y, Yang L. MiR-142-3p blocks TGF-β-induced activation of hepatic stellate cells through targeting TGFβRI. Life Sciences 2017;187:22-30. [DOI: 10.1016/j.lfs.2017.08.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
131 Zhang Z, Guo M, Zhao S, Shao J, Zheng S. ROS-JNK1/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis. Free Radic Biol Med. 2016;101:272-283. [PMID: 27989749 DOI: 10.1016/j.freeradbiomed.2016.10.498] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 11.8] [Reference Citation Analysis]
132 Wu X, Dong W, Zhang T, Ren H, Wang J, Shang L, Zhu Z, Zhu W, Shi X, Xu Y. Epiregulin (EREG) and Myocardin Related Transcription Factor A (MRTF-A) Form a Feedforward Loop to Drive Hepatic Stellate Cell Activation. Front Cell Dev Biol 2020;8:591246. [PMID: 33520984 DOI: 10.3389/fcell.2020.591246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
133 Carpino G, Renzi A, Franchitto A, Cardinale V, Onori P, Reid L, Alvaro D, Gaudio E. Stem/Progenitor Cell Niches Involved in Hepatic and Biliary Regeneration. Stem Cells Int 2016;2016:3658013. [PMID: 26880956 DOI: 10.1155/2016/3658013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
134 甘达凯, 朱萱. RhoA在肝纤维化发生与发展中的作用. 世界华人消化杂志 2016; 24(11): 1682-1687 [DOI: 10.11569/wcjd.v24.i11.1682] [Reference Citation Analysis]
135 Aithal AP, Bairy LK, Seetharam RN, Kumar N. Hepatoprotective effect of bone marrow-derived mesenchymal stromal cells in CCl4-induced liver cirrhosis. 3 Biotech 2021;11:107. [PMID: 33564610 DOI: 10.1007/s13205-021-02640-y] [Reference Citation Analysis]
136 Xiong Y, Huang J. Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment. Chin Med 2021;16:80. [PMID: 34407830 DOI: 10.1186/s13020-021-00489-0] [Reference Citation Analysis]
137 Chen RR, Liu J, Chen Z, Cai WJ, Li XF, Lu CL. Anthraquinones Extract from Morinda angustifolia Roxb. Root Alleviates Hepatic Injury Induced by Carbon Tetrachloride through Inhibition of Hepatic Oxidative Stress. Evid Based Complement Alternat Med 2020;2020:9861571. [PMID: 32328146 DOI: 10.1155/2020/9861571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
138 Hall RA, Hillebrandt S, Lammert F. Exploring multiple quantitative trait loci models of hepatic fibrosis in a mouse intercross. Mamm Genome 2016;27:70-80. [PMID: 26547557 DOI: 10.1007/s00335-015-9609-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
139 Beath SV, Kelly DA. Total Parenteral Nutrition-Induced Cholestasis: Prevention and Management. Clin Liver Dis 2016;20:159-76. [PMID: 26593297 DOI: 10.1016/j.cld.2015.08.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
140 Lyu L, Liu XL, Rui MP, Yang LC, Wang GZ, Fan D, Wang T, Zheng J. Liver extracellular volume fraction values obtained with magnetic resonance imaging can quantitatively stage liver fibrosis: a validation study in monkeys with nonalcoholic steatohepatitis. Eur Radiol 2020;30:5748-57. [PMID: 32377814 DOI: 10.1007/s00330-020-06902-w] [Reference Citation Analysis]
141 Yao J, Liang X, Liu Y, Zheng M. Neddylation: A Versatile Pathway Takes on Chronic Liver Diseases. Front Med (Lausanne) 2020;7:586881. [PMID: 33195347 DOI: 10.3389/fmed.2020.586881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
142 Hou W, Syn WK. Role of Metabolism in Hepatic Stellate Cell Activation and Fibrogenesis. Front Cell Dev Biol. 2018;6:150. [PMID: 30483502 DOI: 10.3389/fcell.2018.00150] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
143 Christ B, Brückner S, Winkler S. The Therapeutic Promise of Mesenchymal Stem Cells for Liver Restoration. Trends Mol Med 2015;21:673-86. [PMID: 26476857 DOI: 10.1016/j.molmed.2015.09.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
144 Sawaf B, Ali AH, Jaafar RF, Kanso M, Mukherji D, Khalife MJ, Faraj W. Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East. Ann Med Surg (Lond) 2020;57:166-70. [PMID: 32774848 DOI: 10.1016/j.amsu.2020.07.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
145 Wang Z, Li J, Xiao W, Long J, Zhang H. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis. Lab Invest 2018;98:1600-13. [DOI: 10.1038/s41374-018-0127-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
146 Li G, Jiang Q, Xu K. CREB family: A significant role in liver fibrosis. Biochimie 2019;163:94-100. [PMID: 31112743 DOI: 10.1016/j.biochi.2019.05.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
147 Yuan X, Gong Z, Wang B, Guo X, Yang L, Li D, Zhang Y. Astragaloside Inhibits Hepatic Fibrosis by Modulation of TGF-β1/Smad Signaling Pathway. Evid Based Complement Alternat Med 2018;2018:3231647. [PMID: 29853950 DOI: 10.1155/2018/3231647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
148 Luo C, Terry JG, Tang Y, Xu K, Massion PP, Landman BA, Carr JJ, Huo Y. Measure Partial Liver Volumetric Variations from Paired Inspiratory-expiratory Chest CT Scans. Proc SPIE Int Soc Opt Eng 2021;11596:37. [PMID: 34354325 DOI: 10.1117/12.2581077] [Reference Citation Analysis]
149 Hara-Chikuma M, Tanaka M, Verkman AS, Yasui M. Inhibition of aquaporin-3 in macrophages by a monoclonal antibody as potential therapy for liver injury. Nat Commun 2020;11:5666. [PMID: 33168815 DOI: 10.1038/s41467-020-19491-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
150 Zhu Y, Hu Y, Cheng X, Li Q, Niu Q. Elevated miR-129-5p attenuates hepatic fibrosis through the NF-κB signaling pathway via PEG3 in a carbon CCl4 rat model. J Mol Histol 2021;52:491-501. [PMID: 33743102 DOI: 10.1007/s10735-020-09949-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
151 El Taghdouini A, van Grunsven LA. Epigenetic regulation of hepatic stellate cell activation and liver fibrosis. Expert Rev Gastroenterol Hepatol 2016;10:1397-408. [PMID: 27762150 DOI: 10.1080/17474124.2016.1251309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
152 Zachou K, Gabeta S, Shums Z, Gatselis NK, Koukoulis GK, Norman GL, Dalekos GN. COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis. Eur J Intern Med. 2017;38:83-88. [PMID: 28100410 DOI: 10.1016/j.ejim.2017.01.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
153 Borthwick LA, Wynn TA. IL-13 and TGF-β1: Core Mediators of Fibrosis. Curr Pathobiol Rep 2015;3:273-82. [DOI: 10.1007/s40139-015-0091-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
154 Tsay HC, Yuan Q, Balakrishnan A, Kaiser M, Möbus S, Kozdrowska E, Farid M, Tegtmeyer PK, Borst K, Vondran FWR, Kalinke U, Kispert A, Manns MP, Ott M, Sharma AD. Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis. J Hepatol 2019;70:722-34. [PMID: 30582979 DOI: 10.1016/j.jhep.2018.12.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
155 Peng W, Cheng S, Bao Z, Wang Y, Zhou W, Wang J, Yang Q, Chen C, Wang W. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomedicine & Pharmacotherapy 2021;137:111342. [DOI: 10.1016/j.biopha.2021.111342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Luli S, Di Paolo D, Perri P, Brignole C, Hill SJ, Brown H, Leslie J, Marshall HL, Wright MC, Mann DA, Ponzoni M, Oakley F. A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo. J Hepatol 2016;65:75-83. [PMID: 27067455 DOI: 10.1016/j.jhep.2016.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
157 Hoshi H, Chu PS, Yoshida A, Taniki N, Morikawa R, Yamataka K, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, Saito H, Kanai T, Nakamoto N. Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis. PLoS One 2021;16:e0250062. [PMID: 33848309 DOI: 10.1371/journal.pone.0250062] [Reference Citation Analysis]
158 Furuhashi H, Tomita K, Teratani T, Shimizu M, Nishikawa M, Higashiyama M, Takajo T, Shirakabe K, Maruta K, Okada Y, Kurihara C, Watanabe C, Komoto S, Aosasa S, Nagao S, Yamamoto J, Miura S, Hokari R. Vitamin A-coupled liposome system targeting free cholesterol accumulation in hepatic stellate cells offers a beneficial therapeutic strategy for liver fibrosis: Targeting free cholesterol in liver fibrosis. Hepatol Res 2018;48:397-407. [DOI: 10.1111/hepr.13040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
159 Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R, Tacke F. Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis. Cells 2019;8:E503. [PMID: 31137713 DOI: 10.3390/cells8050503] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 28.5] [Reference Citation Analysis]
160 Moran-Salvador E, Garcia-Macia M, Sivaharan A, Sabater L, Zaki MYW, Oakley F, Knox A, Page A, Luli S, Mann J, Mann DA. Fibrogenic Activity of MECP2 Is Regulated by Phosphorylation in Hepatic Stellate Cells. Gastroenterology 2019;157:1398-1412.e9. [PMID: 31352003 DOI: 10.1053/j.gastro.2019.07.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
161 Dhingra S, Ward SC, Thung SN. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol 2016; 22(4): 1357-1366 [PMID: 26819505 DOI: 10.3748/wjg.v22.i4.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
162 Hessin AF, Hegazy RR, Hassan AA, Yassin NZ, Kenawy SA. Resveratrol prevents liver fibrosis via two possible pathways: Modulation of alpha fetoprotein transcriptional levels and normalization of protein kinase C responses. Indian J Pharmacol 2017;49:282-9. [PMID: 29326488 DOI: 10.4103/ijp.IJP_299_16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
163 Bedossa P, Hytiroglou P, Yeh MM. Vascular Disorders. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 636-72. [DOI: 10.1016/b978-0-7020-6697-9.00011-x] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
164 Trivella JP, Martin P, Carrion AF. Novel targeted therapies for the management of liver fibrosis. Expert Opinion on Emerging Drugs 2020;25:59-70. [DOI: 10.1080/14728214.2020.1735350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
165 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease? Adv Nutr 2020;11:1696-711. [PMID: 33191435 DOI: 10.1093/advances/nmaa081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
166 He S, Tang J, Diao N, Liao Y, Shi J, Xu X, Xie F, Bai L. Parathyroid hormone-related protein activates HSCs via hedgehog signalling during liver fibrosis development. Artificial Cells, Nanomedicine, and Biotechnology 2019;47:1984-94. [DOI: 10.1080/21691401.2019.1615931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
167 Wilson LH, Cho JH, Estrella A, Smyth JA, Wu R, Chengsupanimit T, Brown LM, Weinstein DA, Lee YM. Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VI. Hepatol Commun 2019;3:1544-55. [PMID: 31701076 DOI: 10.1002/hep4.1426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
168 Wang K, Wang J, Song M, Wang H, Xia N, Zhang Y. Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway. Int J Biol Macromol 2020;162:273-83. [PMID: 32569681 DOI: 10.1016/j.ijbiomac.2020.06.166] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
169 Dufton NP, Peghaire CR, Osuna-Almagro L, Raimondi C, Kalna V, Chauhan A, Webb G, Yang Y, Birdsey GM, Lalor P, Mason JC, Adams DH, Randi AM. Dynamic regulation of canonical TGFβ signalling by endothelial transcription factor ERG protects from liver fibrogenesis. Nat Commun 2017;8:895. [PMID: 29026072 DOI: 10.1038/s41467-017-01169-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
170 Hwang I, Lee EJ, Park H, Moon D, Kim HS. Retinol from hepatic stellate cells via STRA6 induces lipogenesis on hepatocytes during fibrosis. Cell Biosci 2021;11:3. [PMID: 33407858 DOI: 10.1186/s13578-020-00509-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
171 Pierantonelli I, Lioci G, Gurrado F, Giordano DM, Rychlicki C, Bocca C, Trozzi L, Novo E, Panera N, De Stefanis C, D'Oria V, Marzioni M, Maroni L, Parola M, Alisi A, Svegliati-Baroni G. HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation. Liver Int 2020;40:3127-39. [PMID: 33098723 DOI: 10.1111/liv.14712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
172 Zeng XY, Zhang YQ, He XM, Wan LY, Wang H, Ni YR, Wang J, Wu JF, Liu CB. Suppression of hepatic stellate cell activation through downregulation of gremlin1 expression by the miR-23b/27b cluster. Oncotarget 2016;7:86198-210. [PMID: 27863390 DOI: 10.18632/oncotarget.13365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
173 Bohanon FJ, Wang X, Graham BM, Ding C, Ding Y, Radhakrishnan GL, Rastellini C, Zhou J, Radhakrishnan RS. Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis. J Surg Res 2015;199:441-9. [PMID: 26409288 DOI: 10.1016/j.jss.2015.07.042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
174 Nishimura N, De Battista D, McGivern DR, Engle RE, Tice A, Fares-Gusmao R, Kabat J, Pomerenke A, Nguyen H, Sato S, Bock KW, Moore IN, Kleiner DE, Zamboni F, Alter HJ, Govindarajan S, Farci P. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci U S A 2021;118:e2019633118. [PMID: 33888584 DOI: 10.1073/pnas.2019633118] [Reference Citation Analysis]
175 Martínez-Ramírez AS, Díaz-Muñoz M, Butanda-Ochoa A, Vázquez-Cuevas FG. Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). Purinergic Signal 2017;13:1-12. [PMID: 27900516 DOI: 10.1007/s11302-016-9550-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
176 Lighthouse JK, Small EM. Transcriptional control of cardiac fibroblast plasticity. J Mol Cell Cardiol 2016;91:52-60. [PMID: 26721596 DOI: 10.1016/j.yjmcc.2015.12.016] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 10.5] [Reference Citation Analysis]
177 Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1765-78. [DOI: 10.1016/j.bbadis.2015.05.015] [Cited by in Crossref: 127] [Cited by in F6Publishing: 133] [Article Influence: 21.2] [Reference Citation Analysis]
178 Cheng Y, Tian Y, Xia J, Wu X, Yang Y, Li X, Huang C, Meng X, Ma T, Li J. The role of PTEN in regulation of hepatic macrophages activation and function in progression and reversal of liver fibrosis. Toxicol Appl Pharmacol. 2017;317:51-62. [PMID: 28095306 DOI: 10.1016/j.taap.2017.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
179 Zhang Q, Chen K, Wu T, Song H. Swertiamarin ameliorates carbon tetrachloride-induced hepatic apoptosis via blocking the PI3K/Akt pathway in rats. Korean J Physiol Pharmacol 2019;23:21-8. [PMID: 30627006 DOI: 10.4196/kjpp.2019.23.1.21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
180 Negri F, Missale G, Antoni AD, Porta C. Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Transl Oncol 2021;14:101153. [PMID: 34144349 DOI: 10.1016/j.tranon.2021.101153] [Reference Citation Analysis]
181 Varma S, Stéphenne X, Komuta M, Bouzin C, Ambroise J, Smets F, Reding R, Sokal EM. The histological quantification of alpha-smooth muscle actin predicts future graft fibrosis in pediatric liver transplant recipients. Pediatr Transplant 2017;21. [PMID: 27774712 DOI: 10.1111/petr.12834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
182 Li H, Lan J, Han C, Guo K, Wang G, Hu J, Gong J, Luo X, Cao Z. Brg1 promotes liver fibrosis via activation of hepatic stellate cells. Experimental Cell Research 2018;364:191-7. [DOI: 10.1016/j.yexcr.2018.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
183 Martin K, Pritchett J, Llewellyn J, Mullan AF, Athwal VS, Dobie R, Harvey E, Zeef L, Farrow S, Streuli C. PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis. Nat Commun. 2016;7:12502. [PMID: 27535340 DOI: 10.1038/ncomms12502] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 18.0] [Reference Citation Analysis]
184 Altamirano-Barrera A, Barranco-Fragoso B, Méndez-Sánchez N. Management strategies for liver fibrosis. Ann Hepatol 2017;16:48-56. [PMID: 28051792 DOI: 10.5604/16652681.1226814] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 15.3] [Reference Citation Analysis]
185 Han X, Xu S, Lin J. Curcumin Recovers Intracellular Lipid Droplet Formation Through Increasing Perilipin 5 Gene Expression in Activated Hepatic Stellate Cells In Vitro. CURR MED SCI 2019;39:766-77. [DOI: 10.1007/s11596-019-2104-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Cai X, Li Z, Zhang Q, Qu Y, Xu M, Wan X, Lu L. CXCL6-EGFR-induced Kupffer cells secrete TGF-β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/EZH2 pathway in liver fibrosis. J Cell Mol Med 2018;22:5050-61. [PMID: 30106235 DOI: 10.1111/jcmm.13787] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
187 Cheng Y, Zheng H, Wang B, Xu W, Xu J, Zhu Y. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway. Dig Liver Dis 2018;50:381-8. [PMID: 29373239 DOI: 10.1016/j.dld.2017.12.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
188 Bai Y, Wang W, Wang L, Ma L, Zhai D, Wang F, Shi R, Liu C, Xu Q, Chen G, Lu Z. Obacunone Attenuates Liver Fibrosis with Enhancing Anti-Oxidant Effects of GPx-4 and Inhibition of EMT. Molecules 2021;26:E318. [PMID: 33435504 DOI: 10.3390/molecules26020318] [Reference Citation Analysis]
189 Foglia B, Novo E, Protopapa F, Maggiora M, Bocca C, Cannito S, Parola M. Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis. Cells 2021;10:1764. [PMID: 34359934 DOI: 10.3390/cells10071764] [Reference Citation Analysis]
190 Fausther M, G Lavoie E, Dranoff JA. Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants. PLoS One 2017;12:e0184499. [PMID: 28898276 DOI: 10.1371/journal.pone.0184499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Guo C, Dong C, Zhang J, Wang R, Wang Z, Zhou J, Wang W, Ji B, Ma B, Ge Y, Wang Z. An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients. Front Med (Lausanne) 2021;8:716869. [PMID: 34350203 DOI: 10.3389/fmed.2021.716869] [Reference Citation Analysis]
192 Shi X, Li J, Min B, Yang R, He C, Yang Y. Application of ultrasound elastography for monitoring the effects of TβR1 shRNA therapy on hepatic fibrosis in a rat model. PLoS One 2021;16:e0253150. [PMID: 34181670 DOI: 10.1371/journal.pone.0253150] [Reference Citation Analysis]
193 Golder MR, Liu J, Andersen JN, Shipitsin MV, Vohidov F, Nguyen HV, Ehrlich DC, Huh SJ, Vangamudi B, Economides KD, Neenan AM, Ackley JC, Baddour J, Paramasivan S, Brady SW, Held EJ, Reiter LA, Saucier-Sawyer JK, Kopesky PW, Chickering DE, Blume-Jensen P, Johnson JA. Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs. Nat Biomed Eng 2018;2:822-30. [PMID: 30918745 DOI: 10.1038/s41551-018-0279-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
194 Wang Z, Yang X, Kai J, Wang F, Wang Z, Shao J, Tan S, Chen A, Zhang F, Wang S, Zhang Z, Zheng S. HIF-1α-upregulated lncRNA-H19 regulates lipid droplet metabolism through the AMPKα pathway in hepatic stellate cells. Life Sci 2020;255:117818. [PMID: 32445757 DOI: 10.1016/j.lfs.2020.117818] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
195 Yan C, Yang Q, Gong Z. Activation of Hepatic Stellate Cells During Liver Carcinogenesis Requires Fibrinogen/Integrin αvβ5 in Zebrafish. Neoplasia 2018;20:533-42. [PMID: 29649779 DOI: 10.1016/j.neo.2018.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
196 Liu HF, Wang Q, Du YN, Zhu ZH, Li YF, Zou LQ, Xing W. Dynamic contrast-enhanced MRI with Gd-EOB-DTPA for the quantitative assessment of early-stage liver fibrosis induced by carbon tetrachloride in rabbits. Magn Reson Imaging 2020;70:57-63. [PMID: 32325235 DOI: 10.1016/j.mri.2020.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
197 Abdelghany AH, BaSalamah MA, Idris S, Ahmad J, Refaat B. The fibrolytic potentials of vitamin D and thymoquinone remedial therapies: insights from liver fibrosis established by CCl4 in rats. J Transl Med 2016;14:281. [PMID: 27681697 DOI: 10.1186/s12967-016-1040-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
198 Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines 2021;9:365. [PMID: 33807461 DOI: 10.3390/biomedicines9040365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology 2019;70:522-31. [PMID: 30549292 DOI: 10.1002/hep.30418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
200 Zhang H, Ju B, Zhang X, Zhu Y, Nie Y, Xu Y, Lei Q. Magnolol Attenuates Concanavalin A-induced Hepatic Fibrosis, Inhibits CD4+ T Helper 17 (Th17) Cell Differentiation and Suppresses Hepatic Stellate Cell Activation: Blockade of Smad3/Smad4 Signalling. Basic Clin Pharmacol Toxicol 2017;120:560-70. [PMID: 28032440 DOI: 10.1111/bcpt.12749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
201 Xuan J, Zhu D, Cheng Z, Qiu Y, Shao M, Yang Y, Zhai Q, Wang F, Qin F. Crocin inhibits the activation of mouse hepatic stellate cells via the lnc-LFAR1/MTF-1/GDNF pathway. Cell Cycle 2020;19:3480-90. [PMID: 33295246 DOI: 10.1080/15384101.2020.1848064] [Reference Citation Analysis]
202 Novo E, Cannito S, Parola M. In vivo reprogramming of hepatic myofibroblasts into hepatocytes attenuates liver fibrosis: back to the future? Stem Cell Investig 2016;3:53. [PMID: 27777942 DOI: 10.21037/sci.2016.09.08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Chen L, Chen R, Velazquez VM, Brigstock DR. Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p. Am J Pathol. 2016;186:2921-2933. [PMID: 27662798 DOI: 10.1016/j.ajpath.2016.07.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
204 Foglia B, Cannito S, Bocca C, Parola M, Novo E. ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. Int J Mol Sci. 2019;20. [PMID: 31159366 DOI: 10.3390/ijms20112700] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
205 Zhao J, Jiang Y, Sun X, Liu X, Liu F, Song M, Zhang L. The mechanism and role of intracellular α-ketoglutarate reduction in hepatic stellate cell activation. Biosci Rep 2020;40:BSR20193385. [PMID: 32124915 DOI: 10.1042/BSR20193385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39:S60-S63. [PMID: 26206574 DOI: 10.1016/j.clinre.2015.06.015] [Cited by in Crossref: 91] [Cited by in F6Publishing: 90] [Article Influence: 15.2] [Reference Citation Analysis]
207 Ghosh S, Chakraborty J, Goswami A, Bhowmik S, Roy S, Ghosh A, Dokania S, Kumari P, Datta S, Chowdhury A, Bhattacharyya SN, Chatterjee R, Banerjee S. A novel microRNA boosts hyper-β-oxidation of fatty acids in liver by impeding CEP350-mediated sequestration of PPARα and thus restricts chronic hepatitis C. RNA Biol 2020;17:1352-63. [PMID: 32507013 DOI: 10.1080/15476286.2020.1768353] [Reference Citation Analysis]
208 Wu L, Huang XQ, Li N, Xie C, Rao SX, Chen SY, Li F. A magnetic resonance imaging modality for non-invasively distinguishing progression of liver fibrosis by visualizing hepatic platelet-derived growth factor receptor-beta expression in mice. J Gastroenterol Hepatol 2021. [PMID: 34278598 DOI: 10.1111/jgh.15628] [Reference Citation Analysis]
209 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
210 Berasain C, Avila MA. Regulation of hepatocyte identity and quiescence. Cell Mol Life Sci 2015;72:3831-51. [DOI: 10.1007/s00018-015-1970-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
211 Adams DH, Shepherd EL, Lalor PF. Could endothelial TGFβ signaling be a promising new target for liver disease? Expert Rev Gastroenterol Hepatol 2018;12:637-9. [PMID: 29799279 DOI: 10.1080/17474124.2018.1477587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Kulkarni NM, Fung A, Kambadakone AR, Yeh BM. Computed Tomography Techniques, Protocols, Advancements, and Future Directions in Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:305-20. [PMID: 34243919 DOI: 10.1016/j.mric.2021.05.002] [Reference Citation Analysis]
213 Chan YT, Wang N, Tan HY, Li S, Feng Y. Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era? Front Pharmacol 2020;11:548. [PMID: 32425789 DOI: 10.3389/fphar.2020.00548] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
214 El-Tantawy WH, Temraz A. Anti-fibrotic activity of natural products, herbal extracts and nutritional components for prevention of liver fibrosis: review. Arch Physiol Biochem 2019;:1-12. [PMID: 31711319 DOI: 10.1080/13813455.2019.1684952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Pasta L, Pasta F. PAI-1 4G-4G and MTHFR 677TT in non-hepatitis C virus/hepatitis B virus-related liver cirrhosis. World J Hepatol 2015; 7(29): 2920-2926 [PMID: 26689658 DOI: 10.4254/wjh.v7.i29.2920] [Reference Citation Analysis]
216 Abdelsameea E, Alsebaey A, Abdel-Razek W, Ehsan N, Morad W, Salama M, Waked I. Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C. Eur J Gastroenterol Hepatol 2020;32:1553-8. [PMID: 31972660 DOI: 10.1097/MEG.0000000000001672] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
217 O’Rourke JM, Sagar VM, Shah T, Shetty S. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 2018; 24(39): 4436-4447 [PMID: 30357021 DOI: 10.3748/wjg.v24.i39.4436] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 45] [Article Influence: 19.0] [Reference Citation Analysis]
218 Wei H, Song B. Elastography for Longitudinal Assessment of Liver Fibrosis after Antiviral Therapy: A Review. J Clin Transl Hepatol 2020;8:445-53. [PMID: 33447528 DOI: 10.14218/JCTH.2020.00033] [Reference Citation Analysis]
219 McIntosh AT, Wei R, Ahn J, Aouizerat BE, Kassaye SG, Augenbraun MH, Price JC, French AL, Gange SJ, Anastos KM, Goldman R. A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women. PLoS One 2021;16:e0247277. [PMID: 33705408 DOI: 10.1371/journal.pone.0247277] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Zheng Y, Xu YS, Liu Z, Liu HF, Zhai YN, Mao XR, Lei JQ. Whole-Liver Apparent Diffusion Coefficient Histogram Analysis for the Diagnosis and Staging of Liver Fibrosis. J Magn Reson Imaging 2020;51:1745-54. [PMID: 31729811 DOI: 10.1002/jmri.26987] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
221 Miyao M, Kotani H, Ishida T, Kawai C, Manabe S, Abiru H, Tamaki K. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. Lab Invest. 2015;95:1130-1144. [PMID: 26214582 DOI: 10.1038/labinvest.2015.95] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 16.0] [Reference Citation Analysis]
222 Franko A, Kovarova M, Feil S, Feil R, Wagner R, Heni M, Königsrainer A, Ruoß M, Nüssler AK, Weigert C, Häring HU, Lutz SZ, Peter A. cGMP-dependent protein kinase I (cGKI) modulates human hepatic stellate cell activation. Metabolism 2018;88:22-30. [PMID: 30195474 DOI: 10.1016/j.metabol.2018.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
223 Qi B, Fang Q, Liu S, Hou W, Li J, Huang Y, Shi J. Advances of CCR5 antagonists: From small molecules to macromolecules. Eur J Med Chem 2020;208:112819. [PMID: 32947226 DOI: 10.1016/j.ejmech.2020.112819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
224 Ge MX, Liu HT, Zhang N, Niu WX, Lu ZN, Bao YY, Huang R, Yu DK, Shao RG, He HW. Costunolide represses hepatic fibrosis through WW domain-containing protein 2-mediated Notch3 degradation. Br J Pharmacol 2020;177:372-87. [PMID: 31621893 DOI: 10.1111/bph.14873] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
225 Jiang Y, Zhao Y, He F, Wang H. Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice. Hum Gene Ther 2019;30:179-96. [PMID: 30024280 DOI: 10.1089/hum.2018.047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
226 Shi MJ, Yan XL, Dong BS, Yang WN, Su SB, Zhang H. A network pharmacology approach to investigating the mechanism of Tanshinone IIA for the treatment of liver fibrosis. J Ethnopharmacol 2020;253:112689. [PMID: 32101775 DOI: 10.1016/j.jep.2020.112689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
227 Stradiot L, Verhulst S, Roosens T, Øie C, Moya I, Halder G, Mannaerts I, van Grunsven L. Functionality based method for simultaneous isolation of rodent hepatic sinusoidal cells. Biomaterials 2017;139:91-101. [DOI: 10.1016/j.biomaterials.2017.05.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
228 Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis. World J Gastroenterol 2015; 21(36): 10262-10273 [PMID: 26420954 DOI: 10.3748/wjg.v21.i36.10262] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
229 Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatol Res. 2017;47:60-69. [PMID: 27101519 DOI: 10.1111/hepr.12730] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
230 Giannelli G, Mikulits W, Dooley S, Fabregat I, Moustakas A, ten Dijke P, Portincasa P, Winter P, Janssen R, Leporatti S, Herrera B, Sanchez A. The rationale for targeting TGF-β in chronic liver diseases. Eur J Clin Invest 2016;46:349-61. [PMID: 26823073 DOI: 10.1111/eci.12596] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
231 Li L, Duan M, Chen W, Jiang A, Li X, Yang J, Li Z. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J Transl Med 2017;15:111. [PMID: 28535799 DOI: 10.1186/s12967-017-1214-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
232 Xie Z, Wu Y, Liu S, Lai Y, Tang S. LncRNA-SNHG7/miR-29b/DNMT3A axis affects activation, autophagy and proliferation of hepatic stellate cells in liver fibrosis. Clin Res Hepatol Gastroenterol 2021;45:101469. [PMID: 32893175 DOI: 10.1016/j.clinre.2020.05.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
233 Sriphoosanaphan S, Thanapirom K, Kerr SJ, Suksawatamnuay S, Thaimai P, Sittisomwong S, Sonsiri K, Srisoonthorn N, Teeratorn N, Tanpowpong N, Chaopathomkul B, Treeprasertsuk S, Poovorawan Y, Komolmit P. Effect of vitamin D supplementation in patients with chronic hepatitis C after direct-acting antiviral treatment: a randomized, double-blind, placebo-controlled trial. PeerJ 2021;9:e10709. [PMID: 33614272 DOI: 10.7717/peerj.10709] [Reference Citation Analysis]
234 Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers (Basel) 2020;12:E3748. [PMID: 33322158 DOI: 10.3390/cancers12123748] [Reference Citation Analysis]
235 Alhomrani M, Correia J, Zavou M, Leaw B, Kuk N, Xu R, Saad MI, Hodge A, Greening DW, Lim R, Sievert W. The Human Amnion Epithelial Cell Secretome Decreases Hepatic Fibrosis in Mice with Chronic Liver Fibrosis. Front Pharmacol. 2017;8:748. [PMID: 29114223 DOI: 10.3389/fphar.2017.00748] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
236 Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. Eur J Heart Fail. 2018;20:1385-1391. [PMID: 30085383 DOI: 10.1002/ejhf.1286] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
237 Lv Y, Patel N, Zhang HJ. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. Expert Rev Gastroenterol Hepatol 2019;13:1169-80. [PMID: 31774328 DOI: 10.1080/17474124.2019.1697231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
238 González-Fernández B, Sánchez DI, González-Gallego J, Tuñón MJ. Sphingosine 1-Phosphate Signaling as a Target in Hepatic Fibrosis Therapy. Front Pharmacol 2017;8:579. [PMID: 28890699 DOI: 10.3389/fphar.2017.00579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
239 Tu W, Ye J, Wang ZJ. Embryonic liver fordin is involved in glucose glycolysis of hepatic stellate cell by regulating PI3K/Akt signaling. World J Gastroenterol 2016; 22(38): 8519-8527 [PMID: 27784964 DOI: 10.3748/wjg.v22.i38.8519] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
240 Lambrecht J, Verhulst S, Reynaert H, van Grunsven LA. The miRFIB-Score: A Serological miRNA-Based Scoring Algorithm for the Diagnosis of Significant Liver Fibrosis. Cells 2019;8:E1003. [PMID: 31470644 DOI: 10.3390/cells8091003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
241 Seo W, Eun HS, Kim SY, Yi H, Lee Y, Park S, Jang M, Jo E, Kim SC, Han Y, Park K, Jeong W. Exosome-mediated activation of toll-like receptor 3 in stellate cells stimulates interleukin-17 production by γδ T cells in liver fibrosis: Hepatology, Vol. XX, No. X, 2016 Seo et al. Hepatology 2016;64:616-31. [DOI: 10.1002/hep.28644] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 16.8] [Reference Citation Analysis]
242 de Gregorio E, Colell A, Morales A, Marí M. Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int J Mol Sci 2020;21:E3858. [PMID: 32485811 DOI: 10.3390/ijms21113858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
243 Lai C, Feng T, Wei L, Zhang T, Zhou G, Yang Q, Lan T, Xiang G, Yao Y, Zhou L, Huang X. Development and validation of a primate model for liver fibrosis. J Pharmacol Toxicol Methods 2019;100:106600. [PMID: 31247307 DOI: 10.1016/j.vascn.2019.106600] [Reference Citation Analysis]
244 Akil A, Endsley M, Shanmugam S, Saldarriaga O, Somasunderam A, Spratt H, Stevenson HL, Utay NS, Ferguson M, Yi M. Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co-Culture Model System. Sci Rep 2019;9:568. [PMID: 30679661 DOI: 10.1038/s41598-018-37071-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
245 Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis 2020;21:127-38. [PMID: 32108989 DOI: 10.1111/1751-2980.12854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
246 Shi L, Qin E, Zhou J, Zhao J, Nie W, Jiang T, Chen W, Wu D, Huang L, Liu L, Lv L, Zhao M, Zhang Z, Wang F. HIV and HCV Co-Culture Promotes Profibrogenic Gene Expression through an Epimorphin-Mediated ERK Signaling Pathway in Hepatic Stellate Cells. PLoS One 2016;11:e0158386. [PMID: 27362846 DOI: 10.1371/journal.pone.0158386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
247 Milenkovic U, Duponselle J, Bivalacqua TJ, Albersen M. Evolving therapies for Peyronie's disease: how can we work towards new drugs? Transl Androl Urol 2020;9:S284-94. [PMID: 32257869 DOI: 10.21037/tau.2019.08.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Roderfeld M. Matrix metalloproteinase functions in hepatic injury and fibrosis. Matrix Biol. 2018;68-69:452-462. [PMID: 29221811 DOI: 10.1016/j.matbio.2017.11.011] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
249 Özel M, Baskol M, Akalın H, Baskol G. Suberoylanilide Hydroxamic Acid (SAHA) Reduces Fibrosis Markers and Deactivates Human Stellate Cells via the Epithelial-Mesenchymal Transition (EMT). Cell Biochem Biophys 2021;79:349-57. [PMID: 33689126 DOI: 10.1007/s12013-021-00974-1] [Reference Citation Analysis]
250 Armutcu F. Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. Inflamm Res 2019;68:825-39. [PMID: 31327029 DOI: 10.1007/s00011-019-01271-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
251 Pécheur EI. Circulating micro-RNAs as biomarkers of liver fibrosis progression in hepatitis C virus/HIV-1-co-infected patients: a 'miR'-velous opportunity of early diagnosis? AIDS 2021;35:1499-500. [PMID: 34185715 DOI: 10.1097/QAD.0000000000002921] [Reference Citation Analysis]
252 Xu H, Liu L, Cong M, Liu T, Sun S, Ma H, You H, Jia J, Wang P. EGF neutralization antibodies attenuate liver fibrosis by inhibiting myofibroblast proliferation in bile duct ligation mice. Histochem Cell Biol 2020;154:107-16. [PMID: 32180004 DOI: 10.1007/s00418-020-01867-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
253 Xiang DM, Sun W, Ning BF, Zhou TF, Li XF, Zhong W, Cheng Z, Xia MY, Wang X, Deng X, Wang W, Li HY, Cui XL, Li SC, Wu B, Xie WF, Wang HY, Ding J. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018;67:1704-1715. [PMID: 28754776 DOI: 10.1136/gutjnl-2016-313392] [Cited by in Crossref: 62] [Cited by in F6Publishing: 74] [Article Influence: 15.5] [Reference Citation Analysis]
254 Munsterman ID, Kendall TJ, Khelil N, Popa M, Lomme R, Drenth JPH, Tjwa ETTL. Extracellular matrix components indicate remodelling activity in different fibrosis stages of human non-alcoholic fatty liver disease. Histopathology 2018;73:612-21. [PMID: 29856896 DOI: 10.1111/his.13665] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
255 Levada K, Omelyanchik A, Rodionova V, Weiskirchen R, Bartneck M. Magnetic-Assisted Treatment of Liver Fibrosis. Cells 2019;8:E1279. [PMID: 31635053 DOI: 10.3390/cells8101279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
256 Natarajan V, Moeun Y, Kidambi S. Exploring Interactions between Primary Hepatocytes and Non-Parenchymal Cells on Physiological and Pathological Liver Stiffness. Biology (Basel) 2021;10:408. [PMID: 34063016 DOI: 10.3390/biology10050408] [Reference Citation Analysis]
257 Tacke F, Trautwein C. Mechanisms of liver fibrosis resolution. J Hepatol. 2015;63:1038-1039. [PMID: 26232376 DOI: 10.1016/j.jhep.2015.03.039] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 15.0] [Reference Citation Analysis]
258 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol 2018;33:291-7. [PMID: 28548299 DOI: 10.1111/jgh.13834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
259 Parekh D, Natarajan S. Surgical Management of Chronic Pancreatitis. Indian J Surg 2015;77:453-69. [PMID: 26722211 DOI: 10.1007/s12262-015-1362-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
260 Petitclerc L, Sebastiani G, Gilbert G, Cloutier G, Tang A. Liver fibrosis: Review of current imaging and MRI quantification techniques. J Magn Reson Imaging. 2017;45:1276-1295. [PMID: 27981751 DOI: 10.1002/jmri.25550] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 17.8] [Reference Citation Analysis]
261 Caballería L, Torán P, Caballería J. Marcadores de fibrosis hepática. Medicina Clínica 2018;150:310-6. [DOI: 10.1016/j.medcli.2017.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
262 Guha P, Reha J, Katz SC. Immunosuppression in liver tumors: opening the portal to effective immunotherapy. Cancer Gene Ther 2017;24:114-20. [DOI: 10.1038/cgt.2016.54] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
263 Li Y, Liu S, Han M, Lu H, Wang Q, Zhang Y, Tursun K, Li Z, Feng S, Cheng J. NS5ATP13 Promotes Liver Fibrogenesis Via Activation of Hepatic Stellate Cells. J Cell Biochem 2017;118:2463-73. [PMID: 28133777 DOI: 10.1002/jcb.25913] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
264 Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27-42. [PMID: 28506744 DOI: 10.1016/j.addr.2017.05.007] [Cited by in Crossref: 359] [Cited by in F6Publishing: 350] [Article Influence: 89.8] [Reference Citation Analysis]
265 Wu D, Rao Q, Chen W, Ji F, Xie Z, Huang K, Chen E, Zhao Y, Ouyang X, Zhang S, Jiang Z, Zhang L, Xu L, Gao H, Li L. Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B. Liver Int 2018;38:1930-9. [DOI: 10.1111/liv.13756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
266 Lemoinne S, Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Curr Opin Pharmacol 2019;49:60-70. [PMID: 31590120 DOI: 10.1016/j.coph.2019.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
267 Ding H, Fang M, Gong Y, Li D, Zhang C, Wen G, Wu C, Yang J, Yang Y. Smad3 gene C-terminal phosphorylation site mutation aggravates CCl4 -induced inflammation in mice. J Cell Mol Med 2020;24:7044-54. [PMID: 32406200 DOI: 10.1111/jcmm.15385] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
268 Hytiroglou P, Theise ND. Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al. Virchows Arch. 2018;473:15-22. [PMID: 29589101 DOI: 10.1007/s00428-018-2340-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
269 Horst AK, Neumann K, Diehl L, Tiegs G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol. 2016;13:277-292. [PMID: 27041638 DOI: 10.1038/cmi.2015.112] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 23.0] [Reference Citation Analysis]
270 George M, Paci P, Taner T. Significance of progressive liver fibrosis in pediatric liver transplants: A review of current evidence. World J Gastroenterol 2020; 26(17): 1987-1992 [PMID: 32536769 DOI: 10.3748/wjg.v26.i17.1987] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
271 Pozzessere C, Porter K, Kamel I. Surveillance liver MRI for monitoring patients with known or suspected chronic liver disease. Clinical Radiology 2017;72:93.e7-93.e13. [DOI: 10.1016/j.crad.2016.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
272 Li X, Yao QY, Liu HC, Jin QW, Xu BL, Zhang SC, Tu CT. Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease. J Cell Mol Med. 2017;21:2370-2385. [PMID: 28378526 DOI: 10.1111/jcmm.13158] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
273 Pirhonen J, Arola J, Sädevirta S, Luukkonen P, Karppinen SM, Pihlajaniemi T, Isomäki A, Hukkanen M, Yki-Järvinen H, Ikonen E. Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. PLoS One 2016;11:e0147804. [PMID: 26808140 DOI: 10.1371/journal.pone.0147804] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
274 Zhao XK, Yu L, Cheng ML, Che P, Lu YY, Zhang Q, Mu M, Li H, Zhu LL, Zhu JJ, Hu M, Li P, Liang YD, Luo XH, Cheng YJ, Xu ZX, Ding Q. Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis. Sci Rep. 2017;7:4032. [PMID: 28642549 DOI: 10.1038/s41598-017-04317-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
275 Chikamori F, Sharma N, Ito S, Mizobuchi K, Ueta K, Takasugi H, Yukishige S, Matsuoka H, Hokimoto N, Yamai H, Onishi K, Tanida N, Hamaguchi N. Stepwise partial splenic embolization for portal hypertension based on a new concept: Splanchnic caput Medusae. Radiol Case Rep 2021;16:564-70. [PMID: 33408799 DOI: 10.1016/j.radcr.2020.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Zhou L, Dong X, Wang L, Shan L, Li T, Xu W, Ding Y, Lai M, Lin X, Dai M, Bai X, Jia C, Zheng H. Casticin attenuates liver fibrosis and hepatic stellate cell activation by blocking TGF-β/Smad signaling pathway. Oncotarget 2017;8:56267-80. [PMID: 28915589 DOI: 10.18632/oncotarget.17453] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
277 Guo L, Zheng L, Hu L, Zhou H, Yu L, Liang W. Transient Elastography (FibroScan) Performs Better Than Non-Invasive Markers in Assessing Liver Fibrosis and Cirrhosis in Autoimmune Hepatitis Patients. Med Sci Monit 2017;23:5106-12. [PMID: 29073121 DOI: 10.12659/msm.907300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
278 Sasaki Y, Dehnad A, Fish S, Sato A, Jiang J, Tian J, Schröder K, Brandes R, Török NJ. NOX4 Regulates CCR2 and CCL2 mRNA Stability in Alcoholic Liver Disease. Sci Rep 2017;7:46144. [PMID: 28383062 DOI: 10.1038/srep46144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
279 Li RK, Ren XP, Yan FH, Qiang JW, Lin HM, Tao Wang, Zhao HF, Chen WB. Liver fibrosis detection and staging: a comparative study of T1ρ MR imaging and 2D real-time shear-wave elastography. Abdom Radiol (NY) 2018;43:1713-22. [PMID: 29198003 DOI: 10.1007/s00261-017-1381-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
280 Schild MH, Guy CD. Nonalcoholic Steatohepatitis. Surgical Pathology Clinics 2018;11:267-85. [DOI: 10.1016/j.path.2018.02.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
281 Chen X, Zhang D, Wang Y, Chen K, Zhao L, Xu Y, Jiang H, Wang S. Synergistic antifibrotic effects of miR-451 with miR-185 partly by co-targeting EphB2 on hepatic stellate cells. Cell Death Dis 2020;11:402. [PMID: 32467578 DOI: 10.1038/s41419-020-2613-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
282 Fiore EJ, Domínguez LM, Bayo J, García MG, Mazzolini GD. Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: Cells and extracellular vesicles as therapeutic strategies. World J Gastroenterol 2018; 24(23): 2427-2440 [PMID: 29930465 DOI: 10.3748/wjg.v24.i23.2427] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
283 Tan S, Liu H, Ke B, Jiang J, Wu B. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway. Br J Pharmacol 2020;177:2830-47. [PMID: 32017042 DOI: 10.1111/bph.15010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
284 Galina P, Alexopoulou E, Mentessidou A, Mirilas P, Zellos A, Lykopoulou L, Patereli A, Salpasaranis K, Kelekis NL, Zarifi M. Diagnostic accuracy of two-dimensional shear wave elastography in detecting hepatic fibrosis in children with autoimmune hepatitis, biliary atresia and other chronic liver diseases. Pediatr Radiol 2021;51:1358-68. [PMID: 33755748 DOI: 10.1007/s00247-020-04959-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
285 Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J 2016;40:1-11. [PMID: 26912150 DOI: 10.4093/dmj.2016.40.1.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
286 Ramadan A, Afifi N, Yassin NZ, Abdel-Rahman RF, Abd El-Rahman SS, Fayed HM. Mesalazine, an osteopontin inhibitor: The potential prophylactic and remedial roles in induced liver fibrosis in rats. Chem Biol Interact 2018;289:109-18. [PMID: 29738702 DOI: 10.1016/j.cbi.2018.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
287 Bai X, Su G, Zhai S. Recent Advances in Nanomedicine for the Diagnosis and Therapy of Liver Fibrosis. Nanomaterials (Basel) 2020;10:E1945. [PMID: 33003520 DOI: 10.3390/nano10101945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
288 Buechter M, Kersting S, Gerken G, Kahraman A. Enzymatic liver function measured by LiMAx - a reliable diagnostic and prognostic tool in chronic liver disease. Sci Rep 2019;9:13577. [PMID: 31537822 DOI: 10.1038/s41598-019-49746-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
289 Naji KM, Al-Khatib BY, Al-Haj NS, D'souza MR. Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats. BMC Pharmacol Toxicol 2021;22:39. [PMID: 34217369 DOI: 10.1186/s40360-021-00507-9] [Reference Citation Analysis]
290 Abdel-Sattar AR, Abo-Saif AA, Aboyoussef AM. Nicorandil and atorvastatin attenuate carbon tetrachloride - induced liver fibrosis in rats. Immunopharmacol Immunotoxicol 2020;42:582-93. [PMID: 32988255 DOI: 10.1080/08923973.2020.1830104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Park SM, Jung EH, Kim JK, Jegal KH, Park CA, Cho IJ, Kim SC. 20S-Protopanaxadiol, an aglycosylated ginsenoside metabolite, induces hepatic stellate cell apoptosis through liver kinase B1-AMP-activated protein kinase activation. J Ginseng Res 2017;41:392-402. [PMID: 28701883 DOI: 10.1016/j.jgr.2017.01.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
292 Milenkovic U, Ilg MM, Cellek S, Albersen M. Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease. Sexual Medicine Reviews 2019;7:679-89. [DOI: 10.1016/j.sxmr.2019.02.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
293 Fan C, Wu FR, Zhang JF, Jiang H. A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis. Evid Based Complement Alternat Med 2020;2020:4780383. [PMID: 32617108 DOI: 10.1155/2020/4780383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
294 Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol. 2018;12:1143-1152. [PMID: 30261763 DOI: 10.1080/17474124.2018.1530110] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
295 Fiore E, Malvicini M, Bayo J, Peixoto E, Atorrasagasti C, Sierra R, Rodríguez M, Gómez Bustillo S, García MG, Aquino JB, Mazzolini G. Involvement of hepatic macrophages in the antifibrotic effect of IGF-I-overexpressing mesenchymal stromal cells. Stem Cell Res Ther 2016;7:172. [PMID: 27876093 DOI: 10.1186/s13287-016-0424-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
296 Martí-Rodrigo A, Alegre F, Moragrega ÁB, García-García F, Martí-Rodrigo P, Fernández-Iglesias A, Gracia-Sancho J, Apostolova N, Esplugues JV, Blas-García A. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. Gut 2020;69:920-32. [PMID: 31530714 DOI: 10.1136/gutjnl-2019-318372] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
297 Yang Y, Chen XX, Li WX, Wu XQ, Huang C, Xie J, Zhao YX, Meng XM, Li J. EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepatic fibrosis. J Cell Mol Med 2017;21:2317-28. [PMID: 28332284 DOI: 10.1111/jcmm.13153] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
298 Tibaldi E, Brocca A, Sticca A, Gola E, Pizzi M, Bordin L, Pagano MA, Mazzorana M, Donà G, Violi P, Marin O, Romano A, Angeli P, Carraro A, Brunati AM. Fam20C-mediated phosphorylation of osteopontin is critical for its secretion but dispensable for its action as a cytokine in the activation of hepatic stellate cells in liver fibrogenesis. FASEB J 2020;34:1122-35. [PMID: 31914633 DOI: 10.1096/fj.201900880R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
299 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
300 Nah EH, Cho S, Kim S, Kim HS, Cho HI. Diagnostic performance of Mac-2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups. J Clin Lab Anal 2020;34:e23316. [PMID: 32227396 DOI: 10.1002/jcla.23316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
301 Xi S, Zheng X, Li X, Jiang Y, Wu Y, Gong J, Jie Y, Li Z, Cao J, Sha L, Zhang M, Chong Y. Activated Hepatic Stellate Cells Induce Infiltration and Formation of CD163+ Macrophages via CCL2/CCR2 Pathway. Front Med (Lausanne) 2021;8:627927. [PMID: 33614685 DOI: 10.3389/fmed.2021.627927] [Reference Citation Analysis]
302 Xie LT, Xu DX, Tian G, Zhong LY, Zhao QY, Ke QH, Jiang TA. Value of Two-Dimensional Shear Wave Elastography for Assessing Acute Liver Congestion in a Bama Mini-Pig Model. Dig Dis Sci 2018;63:1851-9. [PMID: 29736835 DOI: 10.1007/s10620-018-5085-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
303 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 197] [Cited by in F6Publishing: 192] [Article Influence: 98.5] [Reference Citation Analysis]
304 Labranche R, Gilbert G, Cerny M, Vu KN, Soulières D, Olivié D, Billiard JS, Yokoo T, Tang A. Liver Iron Quantification with MR Imaging: A Primer for Radiologists. Radiographics 2018;38:392-412. [PMID: 29528818 DOI: 10.1148/rg.2018170079] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 14.7] [Reference Citation Analysis]
305 Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151-166. [PMID: 33128017 DOI: 10.1038/s41575-020-00372-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 43] [Article Influence: 31.0] [Reference Citation Analysis]
306 Chen L, Brigstock DR. Integrins and heparan sulfate proteoglycans on hepatic stellate cells (HSC) are novel receptors for HSC-derived exosomes. FEBS Lett. 2016;590:4263-4274. [PMID: 27714787 DOI: 10.1002/1873-3468.12448] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
307 Abbas N, Getachew A, You K, Shah Z, Chen Y, Tao J, Hussain M, Yang F, Zhuang Y, Xu Y, Li YX. Kupffer cells mediate the recruitment of hepatic stellate cells into the localized liver damage. Biochem Biophys Res Commun 2020;529:474-9. [PMID: 32703454 DOI: 10.1016/j.bbrc.2020.06.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
308 Keshavarz Azizi Raftar S, Ashrafian F, Yadegar A, Lari A, Moradi HR, Shahriary A, Azimirad M, Alavifard H, Mohsenifar Z, Davari M, Vaziri F, Moshiri A, Siadat SD, Zali MR. The Protective Effects of Live and Pasteurized Akkermansia muciniphila and Its Extracellular Vesicles against HFD/CCl4-Induced Liver Injury. Microbiol Spectr 2021;9:e0048421. [PMID: 34549998 DOI: 10.1128/Spectrum.00484-21] [Reference Citation Analysis]
309 Zhang ZG, Zou J, Huang Y, Wu L. Kinetin inhibits proliferation of hepatic stellate cells by interrupting cell cycle and induces apoptosis by down-regulating ratio of Bcl-2/Bax. J Huazhong Univ Sci Technolog Med Sci 2015;35:672-8. [PMID: 26489620 DOI: 10.1007/s11596-015-1488-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
310 Yang Q, Yan C, Gong Z. Interaction of hepatic stellate cells with neutrophils and macrophages in the liver following oncogenic kras activation in transgenic zebrafish. Sci Rep 2018;8:8495. [PMID: 29855567 DOI: 10.1038/s41598-018-26612-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
311 Zhang K, Han Y, Hu Z, Zhang Z, Shao S, Yao Q, Zheng L, Wang J, Han X, Zhang Y, Chen T, Yao Z, Han T, Hong W. SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker. Theranostics 2019;9:3622-38. [PMID: 31281502 DOI: 10.7150/thno.32935] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
312 Liu Y, Wu J, Li Z, Luo Y, Zeng F, Shi S. Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study. Eur J Drug Metab Pharmacokinet 2017;42:37-48. [DOI: 10.1007/s13318-015-0316-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
313 Rudnick DA. Antifibrotic therapies in liver disease: Ready for primetime? Clin Liver Dis (Hoboken) 2017;9:138-40. [PMID: 30992978 DOI: 10.1002/cld.641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
314 Fan QQ, Zhang CL, Qiao JB, Cui PF, Xing L, Oh YK, Jiang HL. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials 2020;230:119616. [PMID: 31837823 DOI: 10.1016/j.biomaterials.2019.119616] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
315 Coombes JD, Choi SS, Swiderska-Syn M, Manka P, Reid DT, Palma E, Briones-Orta MA, Xie G, Younis R, Kitamura N. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. Biochim Biophys Acta. 2016;1862:135-144. [PMID: 26529285 DOI: 10.1016/j.bbadis.2015.10.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
316 Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci 2019;76:4869-86. [PMID: 31377844 DOI: 10.1007/s00018-019-03255-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
317 Lu W, Li X, Liu N, Zhang Y, Li Y, Pan Y, Yang J, Liu Z, Kong J. Vitamin D alleviates liver fibrosis by inhibiting histidine-rich calcium binding protein (HRC). Chem Biol Interact 2021;334:109355. [PMID: 33309619 DOI: 10.1016/j.cbi.2020.109355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
318 Francalanci P, Giovannoni I, De Stefanis C, Romito I, Grimaldi C, Castellano A, D'Oria V, Alaggio R, Alisi A. Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5795. [PMID: 32806748 DOI: 10.3390/ijms21165795] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
319 García-Jaramillo M, Lytle KA, Spooner MH, Jump DB. A Lipidomic Analysis of Docosahexaenoic Acid (22:6, ω3) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male Ldlr -/- Mice. Metabolites 2019;9:E252. [PMID: 31661783 DOI: 10.3390/metabo9110252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
320 Shajari S, Laliena A, Heegsma J, Tuñón MJ, Moshage H, Faber KN. Melatonin suppresses activation of hepatic stellate cells through RORα-mediated inhibition of 5-lipoxygenase. J Pineal Res 2015;59:391-401. [PMID: 26308880 DOI: 10.1111/jpi.12271] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
321 Feng S, Tong H, Gao JH, Tang SH, Yang WJ, Wang GM, Zhou HY, Wen SL. Anti-inflammation treatment for protection of hepatocytes and amelioration of hepatic fibrosis in rats. Exp Ther Med 2021;22:1213. [PMID: 34584558 DOI: 10.3892/etm.2021.10647] [Reference Citation Analysis]
322 Akdoğan Ö, Atak Yücel A, Gök Sargin Z, Sönmez C, Esendağli Yilmaz G, Özenirler S. Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD) as Serological Fibrosis Marker. J Clin Exp Hepatol 2019;9:29-33. [PMID: 30765936 DOI: 10.1016/j.jceh.2018.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
323 Dai W, Liu Y, Zhang Y, Sun Y, Sun C, Zhang Y, Lv X. Expression of neuropeptide Y is increased in an activated human HSC cell line. Sci Rep 2019;9:9500. [PMID: 31263154 DOI: 10.1038/s41598-019-45932-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Wan S, Nie Y, Zhang Y, Huang C, Zhu X. Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice. Front Cell Infect Microbiol 2020;10:18. [PMID: 32083022 DOI: 10.3389/fcimb.2020.00018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
325 Wan SZ, Liu C, Huang CK, Luo FY, Zhu X. Ursolic Acid Improves Intestinal Damage and Bacterial Dysbiosis in Liver Fibrosis Mice. Front Pharmacol 2019;10:1321. [PMID: 31736766 DOI: 10.3389/fphar.2019.01321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
326 Poilil Surendran S, George Thomas R, Moon MJ, Jeong YY. Nanoparticles for the treatment of liver fibrosis. Int J Nanomedicine. 2017;12:6997-7006. [PMID: 29033567 DOI: 10.2147/ijn.s145951] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
327 Sirbu D, Luli S, Leslie J, Oakley F, Benniston AC. Enhanced in vivo Optical Imaging of the Inflammatory Response to Acute Liver Injury in C57BL/6 Mice Using a Highly Bright Near‐Infrared BODIPY Dye. ChemMedChem 2019;14:995-9. [DOI: 10.1002/cmdc.201900181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
328 Benbow JH, Elam AD, Bossi KL, Massengill DL, Brandon-Warner E, Anderson WE, Culberson CR, Russo MW, deLemos AS, Schrum LW. Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study. Dig Dis Sci 2018;63:653-64. [PMID: 29330728 DOI: 10.1007/s10620-017-4860-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
329 Deguise MO, Pileggi C, De Repentigny Y, Beauvais A, Tierney A, Chehade L, Michaud J, Llavero-Hurtado M, Lamont D, Atrih A, Wishart TM, Gillingwater TH, Schneider BL, Harper ME, Parson SH, Kothary R. SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2021;12:354-377.e3. [PMID: 33545428 DOI: 10.1016/j.jcmgh.2021.01.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Melgar-Lesmes P, Perramon M, Jiménez W. Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. Cells 2019;8:E1311. [PMID: 31653030 DOI: 10.3390/cells8111311] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
331 Alisi A, Pampanini V, De Stefanis C, Panera N, Deodati A, Nobili V, Cianfarani S. Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. PLoS One 2018;13:e0201566. [PMID: 30063751 DOI: 10.1371/journal.pone.0201566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
332 Tian Y, Li Y, Wang W, Jiang W, Fei J, Li C. Novel Strategy for Validating the Existence and Mechanism of the “Gut–Liver Axis” in Vivo by a Hypoxia-Sensitive NIR Fluorescent Probe. Anal Chem 2020;92:4244-50. [DOI: 10.1021/acs.analchem.9b04578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
333 Parola M. Age-dependent changes in extracellular matrix turnover: An under evaluated issue in the approach to chronic liver diseases. J Hepatol 2016;64:13-5. [PMID: 26432685 DOI: 10.1016/j.jhep.2015.09.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
334 Winkler I, Bitter C, Winkler S, Weichenhan D, Thavamani A, Hengstler JG, Borkham-Kamphorst E, Kohlbacher O, Plass C, Geffers R, Weiskirchen R, Nordheim A. Identification of Pparγ-modulated miRNA hubs that target the fibrotic tumor microenvironment. Proc Natl Acad Sci U S A 2020;117:454-63. [PMID: 31871210 DOI: 10.1073/pnas.1909145117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
335 Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Kohara M, Mizokami M. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial. EBioMedicine 2017;23:79-87. [PMID: 28844410 DOI: 10.1016/j.ebiom.2017.08.016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
336 Li B, Zhang L, Zhang Z, Yan G, Zhu L, Lu W, Yu H. A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis. Eur J Gastroenterol Hepatol 2019;31:218-23. [PMID: 30277926 DOI: 10.1097/MEG.0000000000001281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Huang Y, Chen Y, Zhu H, Li W, Ge Y, Huang X, He J. A liver fibrosis staging method using cross-contrast network. Expert Systems with Applications 2019;130:124-31. [DOI: 10.1016/j.eswa.2019.03.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
338 Hintermann E, Christen U. The Many Roles of Cell Adhesion Molecules in Hepatic Fibrosis. Cells 2019;8:E1503. [PMID: 31771248 DOI: 10.3390/cells8121503] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
339 Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. Mol Aspects Med 2019;65:2-15. [PMID: 29958900 DOI: 10.1016/j.mam.2018.06.003] [Cited by in Crossref: 132] [Cited by in F6Publishing: 133] [Article Influence: 44.0] [Reference Citation Analysis]
340 DeRossi C, Bambino K, Morrison J, Sakarin I, Villacorta-Martin C, Zhang C, Ellis JL, Fiel MI, Ybanez M, Lee YA, Huang KL, Yin C, Sakaguchi TF, Friedman SL, Villanueva A, Chu J. Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. Hepatology 2019;70:2107-22. [PMID: 31016744 DOI: 10.1002/hep.30677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
341 Osna NA, Ganesan M, Seth D, Wyatt TA, Kidambi S, Kharbanda KK. Second hits exacerbate alcohol-related organ damage: an update. Alcohol Alcohol 2021;56:8-16. [PMID: 32869059 DOI: 10.1093/alcalc/agaa085] [Reference Citation Analysis]
342 Zhao Z, Li Y, Jain A, Chen Z, Liu H, Jin W, Cheng K. Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. Nanomedicine 2018;14:51-61. [PMID: 28890106 DOI: 10.1016/j.nano.2017.08.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
343 Alsebaey A, Elhelbawy M, Waked I. Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease. Eur J Gastroenterol Hepatol. 2018;30:207-211. [PMID: 29240565 DOI: 10.1097/meg.0000000000001013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
344 Vasseur P, Pohin M, Jégou J, Favot L, Venisse N, Mcheik J, Morel F, Lecron J, Silvain C. Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis. Br J Dermatol 2018;179:101-9. [DOI: 10.1111/bjd.16137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
345 You Z, Zhou L, Li W, Huang C, Du Y. Mechanical microenvironment as a key cellular regulator in the liver. Acta Mech Sin 2019;35:289-98. [DOI: 10.1007/s10409-019-00857-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
346 Wirtz TH, Brandt EF, Berres ML. Liver DCs in health and disease. Int Rev Cell Mol Biol 2019;348:263-99. [PMID: 31810555 DOI: 10.1016/bs.ircmb.2019.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
347 Tan S, Lu Y, Xu M, Huang X, Liu H, Jiang J, Wu B. β‐Arrestin1 enhances liver fibrosis through autophagy‐mediated Snail signaling. FASEB j 2018;33:2000-16. [DOI: 10.1096/fj.201800828rr] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
348 Ai Y, Shi W, Zuo X, Sun X, Chen Y, Wang Z, Li R, Song X, Dai W, Mu W, Ding K, Li Z, Li Q, Xiao X, Zhan X, Bai Z. The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis Via Modulating Multiple Signaling Pathways in Mice. Front Pharmacol 2021;12:655531. [PMID: 34149411 DOI: 10.3389/fphar.2021.655531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
349 Cai X, Wang J, Wang J, Zhou Q, Yang B, He Q, Weng Q. Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy. Pharmacol Res 2020;155:104720. [PMID: 32092405 DOI: 10.1016/j.phrs.2020.104720] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
350 Wood GC, Chu X, Argyropoulos G, Benotti P, Rolston D, Mirshahi T, Petrick A, Gabrielson J, Carey DJ, DiStefano JK, Still CD, Gerhard GS. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep 2017;7:43238. [PMID: 28266614 DOI: 10.1038/srep43238] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
351 Liu X, Mi X, Wang Z, Zhang M, Hou J, Jiang S, Wang Y, Chen C, Li W. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway. Cell Death Dis 2020;11:454. [PMID: 32532964 DOI: 10.1038/s41419-020-2597-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
352 Catani L, Sollazzo D, Bianchi E, Ciciarello M, Antoniani C, Foscoli L, Caraceni P, Giannone FA, Baldassarre M, Giordano R, Montemurro T, Montelatici E, D'Errico A, Andreone P, Giudice V, Curti A, Manfredini R, Lemoli RM. Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. Cytotherapy 2017;19:1447-61. [PMID: 28917627 DOI: 10.1016/j.jcyt.2017.08.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
353 Liu Y, Nong L, Jia Y, Tan A, Duan L, Lu Y, Zhao J. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway. Aging (Albany NY) 2020;12:6058-66. [PMID: 32283542 DOI: 10.18632/aging.103002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
354 Nwosu ZC, Alborzinia H, Wölfl S, Dooley S, Liu Y. Evolving Insights on Metabolism, Autophagy, and Epigenetics in Liver Myofibroblasts. Front Physiol 2016;7:191. [PMID: 27313533 DOI: 10.3389/fphys.2016.00191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
355 Klindt C, Reich M, Hellwig B, Stindt J, Rahnenführer J, Hengstler JG, Köhrer K, Schoonjans K, Häussinger D, Keitel V. The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver. Cells 2019;8:E1467. [PMID: 31752395 DOI: 10.3390/cells8111467] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
356 Scheving LA, Zhang X, Threadgill DW, Russell WE. Hepatocyte ERBB3 and EGFR are required for maximal CCl4-induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2016;311:G807-16. [PMID: 27586651 DOI: 10.1152/ajpgi.00423.2015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
357 Jiang QQ, Liu BB, Xu KS. New insights into BMP9 signaling in liver diseases. Mol Cell Biochem 2021;476:3591-600. [PMID: 34019202 DOI: 10.1007/s11010-021-04182-6] [Reference Citation Analysis]
358 Valentino G, Zivko C, Weber F, Brülisauer L, Luciani P. Synergy of Phospholipid-Drug Formulations Significantly Deactivates Profibrogenic Human Hepatic Stellate Cells. Pharmaceutics 2019;11:E676. [PMID: 31842373 DOI: 10.3390/pharmaceutics11120676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
359 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Reference Citation Analysis]
360 Shen DF, Cheng H, Cai BZ, Cai WF, Wang B, Zhu Q, Wu YB, Liu M, Chen RJ, Gao FF, Zhang YM, Niu YD, Shi GG. N-n-Butyl haloperidol iodide ameliorates liver fibrosis and hepatic stellate cell activation in mice. Acta Pharmacol Sin 2021. [PMID: 33758354 DOI: 10.1038/s41401-021-00630-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Cai W, Xu H, Zhang B, Gao X, Li S, Wei Z, Li S, Mao N, Jin F, Li Y, Liu H, Yang F. Differential expression of lncRNAs during silicosis and the role of LOC103691771 in myofibroblast differentiation induced by TGF-β1. Biomed Pharmacother 2020;125:109980. [PMID: 32028236 DOI: 10.1016/j.biopha.2020.109980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
362 Magdy M, Fahmy A, Zaki NI, Mohamed AK. Prophylactic versus therapeutic role of the transplanted CD34+ Umbilical Cord Blood Stem Cells and Wharton Jelly Mesenchymal Stem Cells in early / acute hepatic S. mansoni granulomas reversal in mice; a novel approach. Exp Parasitol 2020;217:107938. [PMID: 32768560 DOI: 10.1016/j.exppara.2020.107938] [Reference Citation Analysis]
363 Wang XP, Wang Y, Ma H, Wang H, Yang DW, Zhao XY, Jin EH, Yang ZH. Assessment of liver fibrosis with liver and spleen magnetic resonance elastography, serum markers in chronic liver disease. Quant Imaging Med Surg 2020;10:1208-22. [PMID: 32550131 DOI: 10.21037/qims-19-849] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
364 Novo E, Bocca C, Foglia B, Protopapa F, Maggiora M, Parola M, Cannito S. Liver fibrogenesis: un update on established and emerging basic concepts. Arch Biochem Biophys 2020;689:108445. [PMID: 32524998 DOI: 10.1016/j.abb.2020.108445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
365 Oancea CN, Butaru AE, Streba CT, Pirici D, Rogoveanu I, Diculescu MM, Gheonea DI. Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. Rom J Morphol Embryol 2020;61:643-53. [PMID: 33817705 DOI: 10.47162/RJME.61.3.02] [Reference Citation Analysis]
366 LaPrade RF, Dragoo JL, Koh JL, Murray IR, Geeslin AG, Chu CR. AAOS Research Symposium Updates and Consensus: Biologic Treatment of Orthopaedic Injuries. J Am Acad Orthop Surg 2016;24:e62-78. [PMID: 27227987 DOI: 10.5435/JAAOS-D-16-00086] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
367 Chen Q, Chen L, Wu X, Zhang F, Jin H, Lu C, Shao J, Kong D, Wu L, Zheng S. Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway: DHA Prevents Hepatic Fibrosis by Inducing HSC Apoptosis. IUBMB Life 2016;68:220-31. [DOI: 10.1002/iub.1478] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
368 Li X, Wang H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease. Cell Biosci 2020;10:140. [PMID: 33372630 DOI: 10.1186/s13578-020-00507-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
369 Fan J, Chen Q, Wei L, Zhou X, Wang R, Zhang H. Asiatic acid ameliorates CCl4-induced liver fibrosis in rats: involvement of Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways. Drug Des Devel Ther 2018;12:3595-605. [PMID: 30464391 DOI: 10.2147/DDDT.S179876] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
370 Wu C, Chen W, Ding H, Li D, Wen G, Zhang C, Lu W, Chen M, Yang Y. Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho-Smad2/3 at linker regions in vivo and in vitro. Life Sciences 2019;239:116881. [DOI: 10.1016/j.lfs.2019.116881] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
371 Chen H, Gan Q, Yang C, Peng X, Qin J, Qiu S, Jiang Y, Tu S, He Y, Li S, Yang H, Tao L, Peng Y. A novel role of glutathione S-transferase A3 in inhibiting hepatic stellate cell activation and rat hepatic fibrosis. J Transl Med 2019;17:280. [PMID: 31443720 DOI: 10.1186/s12967-019-2027-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
372 Pan LX, Li LY, Zhou H, Cheng SQ, Liu YM, Lian PP, Li L, Wang LL, Rong SJ, Shen CP, Li J, Xu T. TMEM100 mediates inflammatory cytokines secretion in hepatic stellate cells and its mechanism research. Toxicol Lett 2019;317:82-91. [PMID: 30639579 DOI: 10.1016/j.toxlet.2018.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
373 Milenkovic U, Albersen M, Castiglione F. The mechanisms and potential of stem cell therapy for penile fibrosis. Nat Rev Urol 2019;16:79-97. [DOI: 10.1038/s41585-018-0109-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
374 Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(17): 1993-2011 [PMID: 32536770 DOI: 10.3748/wjg.v26.i17.1993] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
375 Zhang K, Han X, Zhang Z, Zheng L, Hu Z, Yao Q, Cui H, Shu G, Si M, Li C, Shi Z, Chen T, Han Y, Chang Y, Yao Z, Han T, Hong W. The liver-enriched lnc-LFAR1 promotes liver fibrosis by activating TGFβ and Notch pathways. Nat Commun 2017;8:144. [PMID: 28747678 DOI: 10.1038/s41467-017-00204-4] [Cited by in Crossref: 98] [Cited by in F6Publishing: 109] [Article Influence: 24.5] [Reference Citation Analysis]
376 Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V; LIDO (Liver Injury in Diabetes and Obesity) Study Group. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol 2020;72:828-38. [PMID: 31862486 DOI: 10.1016/j.jhep.2019.12.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
377 Rókusz A, Nagy E, Gerlei Z, Veres D, Dezső K, Paku S, Szücs A, Hajósi-kalcakosz S, Pávai Z, Görög D, Kóbori L, Fehérvári I, Nemes B, Nagy P. Quantitative morphometric and immunohistochemical analysis and their correlates in cirrhosis – A study on explant livers. Scandinavian Journal of Gastroenterology 2015;51:86-94. [DOI: 10.3109/00365521.2015.1067902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
378 Ji D, Chen Y, Shang Q, Liu H, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Hu X, Wang X, Chen D, Li Z, Dong Z, Chen G, Yang Y. Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B. Am J Gastroenterol 2021. [PMID: 33840727 DOI: 10.14309/ajg.0000000000001239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Galler K, Fröhlich E, Kortgen A, Bauer M, Popp J, Neugebauer U. Hepatic cirrhosis and recovery as reflected by Raman spectroscopy: information revealed by statistical analysis might lead to a prognostic biomarker. Anal Bioanal Chem 2016;408:8053-63. [DOI: 10.1007/s00216-016-9905-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
380 Ehrlich L, Scrushy M, Meng F, Lairmore TC, Alpini G, Glaser S. Biliary epithelium: A neuroendocrine compartment in cholestatic liver disease. Clin Res Hepatol Gastroenterol 2018;42:296-305. [PMID: 29678444 DOI: 10.1016/j.clinre.2018.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
381 Arab JP, Cabrera D, Sehrawat TS, Jalan-Sakrikar N, Verma VK, Simonetto D, Cao S, Yaqoob U, Leon J, Freire M, Vargas JI, De Assuncao TM, Kwon JH, Guo Y, Kostallari E, Cai Q, Kisseleva T, Oh Y, Arrese M, Huebert RC, Shah VH. Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. J Hepatol 2020;73:149-60. [PMID: 32087348 DOI: 10.1016/j.jhep.2020.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
382 Hayashi A, Shibahara J, Misumi K, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M. Histologic Assessment of Intratumoral Lymphoplasmacytic Infiltration Is Useful in Predicting Prognosis of Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0155744. [PMID: 27195977 DOI: 10.1371/journal.pone.0155744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
383 Guzman-Lepe J, Cervantes-Alvarez E, Collin de l'Hortet A, Wang Y, Mars WM, Oda Y, Bekki Y, Shimokawa M, Wang H, Yoshizumi T, Maehara Y, Bell A, Fox IJ, Takeishi K, Soto-Gutierrez A. Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. Hepatol Commun 2018;2:582-94. [PMID: 29761173 DOI: 10.1002/hep4.1172] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
384 Liu Y, Li L, Liu J, She WM, Shi JM, Li J, Wang JY, Jiang W. Activated hepatic stellate cells directly induce pathogenic Th17 cells in chronic hepatitis B virus infection. Exp Cell Res. 2017;359:129-137. [PMID: 28780305 DOI: 10.1016/j.yexcr.2017.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
385 Gan D, Zhang W, Huang C, Chen J, He W, Wang A, Li B, Zhu X. Ursolic acid ameliorates CCl4-induced liver fibrosis through the NOXs/ROS pathway. J Cell Physiol 2018;233:6799-813. [PMID: 29672850 DOI: 10.1002/jcp.26541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
386 Yang JJ, Tao H, Liu LP, Hu W, Deng ZY, Li J. miR-200a controls hepatic stellate cell activation and fibrosis via SIRT1/Notch1 signal pathway. Inflamm Res 2017;66:341-52. [PMID: 28025657 DOI: 10.1007/s00011-016-1020-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
387 Nair PR, Alvey C, Jin X, Irianto J, Ivanovska I, Discher DE. Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 2018;29:914-27. [PMID: 29451777 DOI: 10.1021/acs.bioconjchem.7b00816] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
388 Shi Y, Leng Y, Liu D, Liu X, Ren Y, Zhang J, Chen F. Research Advances in Protective Effects of Ursolic Acid and Oleanolic Acid Against Gastrointestinal Diseases. Am J Chin Med 2021;49:413-35. [PMID: 33622215 DOI: 10.1142/S0192415X21500191] [Reference Citation Analysis]
389 Agarwal T, Banerjee D, Konwarh R, Esworthy T, Kumari J, Onesto V, Das P, Lee BH, Wagener FADTG, Makvandi P, Mattoli V, Ghosh SK, Maiti TK, Zhang LG, Ozbolat IT. Recent advances in bioprinting technologies for engineering hepatic tissue. Mater Sci Eng C Mater Biol Appl 2021;123:112013. [PMID: 33812632 DOI: 10.1016/j.msec.2021.112013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
390 Cai Y, Huang G, Ma L, Dong L, Chen S, Shen X, Zhang S, Xue R, Sun D, Zhang S. Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and attenuates liver fibrosis through miR-132 mediated CTGF inhibition. Biochim Biophys Acta Mol Cell Res 2018;1865:297-308. [PMID: 29100790 DOI: 10.1016/j.bbamcr.2017.10.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
391 Huang WJ, Zhou X, Fu GB, Ding M, Wu HP, Zeng M, Zhang HD, Xu LY, Gao Y, Wang HY, Yan HX. The combined induction of liver progenitor cells and the suppression of stellate cells by small molecules reverts chronic hepatic dysfunction. Theranostics 2021;11:5539-52. [PMID: 33859762 DOI: 10.7150/thno.54457] [Reference Citation Analysis]
392 Rókusz A, Veres D, Szücs A, Bugyik E, Mózes M, Paku S, Nagy P, Dezső K. Ductular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models. PLoS One 2017;12:e0176518. [PMID: 28445529 DOI: 10.1371/journal.pone.0176518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
393 Zhao J, Fan Y, Wang K, Ni X, Gu J, Lu H, Lu Y, Lu L, Dai X, Wang X. LncRNA HULC affects the differentiation of Treg in HBV-related liver cirrhosis. International Immunopharmacology 2015;28:901-5. [DOI: 10.1016/j.intimp.2015.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
394 van der Helm D, Barnhoorn MC, de Jonge-Muller ESM, Molendijk I, Hawinkels LJAC, Coenraad MJ, van Hoek B, Verspaget HW. Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers. J Cell Mol Med 2019;23:6238-50. [PMID: 31245923 DOI: 10.1111/jcmm.14508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
395 Yang JH, Kim SC, Kim KM, Jang CH, Cho SS, Kim SJ, Ku SK, Cho IJ, Ki SH. Isorhamnetin attenuates liver fibrosis by inhibiting TGF-β/Smad signaling and relieving oxidative stress. European Journal of Pharmacology 2016;783:92-102. [DOI: 10.1016/j.ejphar.2016.04.042] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 11.0] [Reference Citation Analysis]
396 Li H, You H, Fan X, Jia J. Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets. BMJ Open Gastroenterol. 2016;3:e000079. [PMID: 27252881 DOI: 10.1136/bmjgast-2016-000079] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
397 Tsuchida T, Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou HI, Hoshida Y, Friedman SL. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 2018;69:385-95. [PMID: 29572095 DOI: 10.1016/j.jhep.2018.03.011] [Cited by in Crossref: 106] [Cited by in F6Publishing: 114] [Article Influence: 35.3] [Reference Citation Analysis]
398 Sun YY, Li XF, Meng XM, Huang C, Zhang L, Li J. Macrophage Phenotype in Liver Injury and Repair. Scand J Immunol. 2017;85:166-174. [PMID: 27491503 DOI: 10.1111/sji.12468] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
399 Komolmit P, Kimtrakool S, Suksawatamnuay S, Thanapirom K, Chattrasophon K, Thaimai P, Chirathaworn C, Poovorawan Y. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study. Sci Rep 2017;7:8905. [PMID: 28827788 DOI: 10.1038/s41598-017-09512-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
400 Nishikawa K, Osawa Y, Kimura K. Wnt/β-Catenin Signaling as a Potential Target for the Treatment of Liver Cirrhosis Using Antifibrotic Drugs. Int J Mol Sci 2018;19:E3103. [PMID: 30308992 DOI: 10.3390/ijms19103103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
401 Ji J, Yu Q, Dai W, Wu L, Feng J, Zheng Y, Li Y, Guo C. Apigenin Alleviates Liver Fibrosis by Inhibiting Hepatic Stellate Cell Activation and Autophagy via TGF-β1/Smad3 and p38/PPARα Pathways. PPAR Res 2021;2021:6651839. [PMID: 33574836 DOI: 10.1155/2021/6651839] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 Finamor IA, Bressan CA, Torres-Cuevas I, Rius-Pérez S, da Veiga M, Rocha MI, Pavanato MA, Pérez S. Long-Term Aspartame Administration Leads to Fibrosis, Inflammasome Activation, and Gluconeogenesis Impairment in the Liver of Mice. Biology (Basel) 2021;10:82. [PMID: 33499218 DOI: 10.3390/biology10020082] [Reference Citation Analysis]
403 Mai ZH, Huang Y, Huang D, Huang ZS, He ZX, Li PL, Zhang S, Weng JF, Gu WL. Reversine and herbal Xiang-Sha-Liu-Jun-Zi decoction ameliorate thioacetamide-induced hepatic injury by regulating the RelA/NF-κB/caspase signaling pathway. Open Life Sci 2020;15:696-710. [PMID: 33817258 DOI: 10.1515/biol-2020-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Tang X, Xie X, Wang X, Wang Y, Jiang X, Jiang H. The Combination of piR-823 and Eukaryotic Initiation Factor 3 B (EIF3B) Activates Hepatic Stellate Cells via Upregulating TGF-β1 in Liver Fibrogenesis. Med Sci Monit 2018;24:9151-65. [PMID: 30556540 DOI: 10.12659/MSM.914222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
405 Lian N, Jin H, Zhang F, Wu L, Shao J, Lu Y, Zheng S. Curcumin inhibits aerobic glycolysis in hepatic stellate cells associated with activation of adenosine monophosphate-activated protein kinase: Curcumin inhibits aerobic glycolysis in HSCs. IUBMB Life 2016;68:589-96. [DOI: 10.1002/iub.1518] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
406 Florentino RM, Fraunhoffer NA, Morita K, Takeishi K, Ostrowska A, Achreja A, Animasahun O, Haep N, Arazov S, Agarwal N, Collin de l'Hortet A, Guzman-Lepe J, Tafaleng EN, Mukherjee A, Troy K, Banerjee S, Paranjpe S, Michalopoulos GK, Bell A, Nagrath D, Hainer SJ, Fox IJ, Soto-Gutierrez A. Cellular Location of HNF4α is Linked With Terminal Liver Failure in Humans. Hepatol Commun 2020;4:859-75. [PMID: 32490322 DOI: 10.1002/hep4.1505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
407 Feng J, Chen K, Xia Y, Wu L, Li J, Li S, Wang W, Lu X, Liu T, Guo C. Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways. Drug Des Devel Ther 2018;12:1837-53. [PMID: 29970958 DOI: 10.2147/DDDT.S162950] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 9.7] [Reference Citation Analysis]
408 吴兰婷, 刘文兰. 肝纤维化逆转机制的研究进展及治疗概况. 世界华人消化杂志 2017; 25(23): 2123-2132 [DOI: 10.11569/wcjd.v25.i23.2123] [Reference Citation Analysis]
409 Esteban JPG, Asgharpour A. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. Gastroenterol Clin North Am. 2020;49:105-121. [PMID: 32033758 DOI: 10.1016/j.gtc.2019.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Liu H, Zhang S, Xu S, Koroleva M, Small EM, Jin ZG. Myofibroblast-specific YY1 promotes liver fibrosis. Biochem Biophys Res Commun 2019;514:913-8. [PMID: 31084931 DOI: 10.1016/j.bbrc.2019.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
411 Majo J, Klinkhammer BM, Boor P, Tiniakos D. Pathology and natural history of organ fibrosis. Curr Opin Pharmacol 2019;49:82-9. [PMID: 31671319 DOI: 10.1016/j.coph.2019.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
412 Li J, Wang Y, Ma M, Jiang S, Zhang X, Zhang Y, Yang X, Xu C, Tian G, Li Q, Wang Y, Zhu L, Nie H, Feng M, Xia Q, Gu J, Xu Q, Zhang Z. Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling. EBioMedicine 2019;40:43-55. [PMID: 30639416 DOI: 10.1016/j.ebiom.2019.01.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
413 Wang Y, Yang Z, Wei Y, Li X, Li S. Apolipoprotein A4 regulates the immune response in carbon tetrachloride-induced chronic liver injury in mice. Int Immunopharmacol 2021;90:107222. [PMID: 33276196 DOI: 10.1016/j.intimp.2020.107222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
414 O'Shea A, Pierce TT. US Elastography in Hepatic Fibrosis-Radiology In Training. Radiology 2021;299:264-71. [PMID: 33754829 DOI: 10.1148/radiol.2021203893] [Reference Citation Analysis]
415 Lu SQ, Feng JY, Liu J, Xie XB, Lu Y, Abuduxikuer K. Glycogen storage disease type VI can progress to cirrhosis: ten Chinese patients with GSD VI and a literature review. J Pediatr Endocrinol Metab 2020;33:1321-33. [PMID: 32892177 DOI: 10.1515/jpem-2020-0173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Wei F, Guo L, Xu Y, Chen D, Gong M. Comparative Pharmacokinetic Study of Taxifolin after Oral Administration of Fructus Polygoni Orientalis Extract in Normal and Fibrotic Rats by UPLC-MS/MS. Evid Based Complement Alternat Med 2019;2019:9348075. [PMID: 31976002 DOI: 10.1155/2019/9348075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Vilas-Boas V, Cooreman A, Gijbels E, Van Campenhout R, Gustafson E, Ballet S, Annaert P, Cogliati B, Vinken M. Primary hepatocytes and their cultures for the testing of drug-induced liver injury. Adv Pharmacol 2019;85:1-30. [PMID: 31307583 DOI: 10.1016/bs.apha.2018.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
418 Zhang Z, Zhao S, Yao Z, Wang L, Shao J, Chen A, Zhang F, Zheng S. Autophagy regulates turnover of lipid droplets via ROS-dependent Rab25 activation in hepatic stellate cell. Redox Biol. 2017;11:322-334. [PMID: 28038427 DOI: 10.1016/j.redox.2016.12.021] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
419 Gan J, Mao XR, Zheng SJ, Li JF. Invariant natural killer T cells: Not to be ignored in liver disease. J Dig Dis 2021;22:136-42. [PMID: 33421264 DOI: 10.1111/1751-2980.12968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
420 Haep N, Florentino RM, Squires JE, Bell A, Soto-Gutierrez A. The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone. Semin Liver Dis 2021;41:213-24. [PMID: 33992030 DOI: 10.1055/s-0041-1725023] [Reference Citation Analysis]
421 Brückner S, Zipprich A, Hempel M, Thonig A, Schwill F, Roderfeld M, Roeb E, Christ B. Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue–derived mesenchymal stromal cells. Cytotherapy 2017;19:1462-73. [DOI: 10.1016/j.jcyt.2017.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
422 Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit Rev Clin Lab Sci 2016;53:396-408. [PMID: 27187575 DOI: 10.1080/10408363.2016.1190683] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
423 Tsai MC, Yen YH, Chang KC, Hung CH, Chen CH, Lin MT, Hu TH. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection. BMC Cancer 2019;19:1169. [PMID: 31791275 DOI: 10.1186/s12885-019-6397-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
424 Zhao Z, Lin CY, Cheng K. siRNA- and miRNA-based therapeutics for liver fibrosis. Transl Res 2019;214:17-29. [PMID: 31476281 DOI: 10.1016/j.trsl.2019.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
425 Ezhilarasan D, Evraerts J, Brice S, Buc-Calderon P, Karthikeyan S, Sokal E, Najimi M. Silibinin Inhibits Proliferation and Migration of Human Hepatic Stellate LX-2 Cells. J Clin Exp Hepatol 2016;6:167-74. [PMID: 27746612 DOI: 10.1016/j.jceh.2016.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
426 Natarajan V, Harris EN, Kidambi S. SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis. Biomed Res Int. 2017;2017:4097205. [PMID: 28293634 DOI: 10.1155/2017/4097205] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
427 Shan C, Wang R, Wang S, Zhang Z, Xing C, Feng W, Zhao Z, Zhou S, Zhao AZ, Mu Y, Li F. Endogenous production of n-3 polyunsaturated fatty acids protects mice from carbon tetrachloride-induced liver fibrosis by regulating mTOR and Bcl-2/Bax signalling pathways. Exp Physiol 2021;106:983-93. [PMID: 33605486 DOI: 10.1113/EP089328] [Reference Citation Analysis]
428 Ma P, Gao C, Yi J, Zhao J, Liang S, Zhao Y, Ye Y, Bai J, Zheng Q, Dou K, Han H, Qin H. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice. Journal of Hepatology 2017;67:770-9. [DOI: 10.1016/j.jhep.2017.05.022] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 16.3] [Reference Citation Analysis]
429 Bansal R, van Baarlen J, Storm G, Prakash J. The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Sci Rep. 2015;5:18272. [PMID: 26658360 DOI: 10.1038/srep18272] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
430 Potthoff A, Schettler A, Attia D, Schlue J, Schmitto JD, Fegbeutel C, Strüber M, Haverich A, Manns MP, Wedemeyer H, Gebel M, Schneider A. Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. J Heart Lung Transplant 2015;34:1586-94. [PMID: 26169664 DOI: 10.1016/j.healun.2015.05.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
431 Huang C, Gan D, Luo F, Wan S, Chen J, Wang A, Li B, Zhu X. Interaction Mechanisms Between the NOX4/ROS and RhoA/ROCK1 Signaling Pathways as New Anti- fibrosis Targets of Ursolic Acid in Hepatic Stellate Cells. Front Pharmacol 2019;10:431. [PMID: 31130857 DOI: 10.3389/fphar.2019.00431] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
432 Perry RJ. Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis. Obesity (Silver Spring) 2019;27:1385-7. [PMID: 31343116 DOI: 10.1002/oby.22559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
433 Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Llerena S, Huelin P, Fábrega E, Crespo J. LOXL2-A New Target in Antifibrogenic Therapy? Int J Mol Sci 2019;20:E1634. [PMID: 30986934 DOI: 10.3390/ijms20071634] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
434 Lytle KA, Wong CP, Jump DB. Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice. PLoS One 2017;12:e0173376. [PMID: 28422962 DOI: 10.1371/journal.pone.0173376] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
435 Dong H, Guo H, Liang Y, Wang X, Niu Y. Astragaloside IV synergizes with ferulic acid to suppress hepatic stellate cells activation in vitro. Free Radic Res 2017;51:167-78. [PMID: 28147890 DOI: 10.1080/10715762.2017.1290233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
436 Liu X, Huang K, Niu Z, Mei D, Zhang B. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice. Basic Clin Pharmacol Toxicol 2019;124:144-53. [PMID: 30180301 DOI: 10.1111/bcpt.13122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
437 Vollmar J, Kim YO, Marquardt JU, Becker D, Galle PR, Schuppan D, Zimmermann T. Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019;317:G195-202. [DOI: 10.1152/ajpgi.00088.2019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
438 Asgharpour A, Dinani A, Friedman SL. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry. Transl Gastroenterol Hepatol 2021;6:5. [PMID: 33409399 DOI: 10.21037/tgh.2020.01.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Sferra R, Vetuschi A, Pompili S, Gaudio E, Speca S, Latella G. Expression of pro-fibrotic and anti-fibrotic molecules in dimethylnitrosamine-induced hepatic fibrosis. Pathol Res Pract 2017;213:58-65. [PMID: 27894619 DOI: 10.1016/j.prp.2016.11.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
440 Zehra M, Curry JC, Pillai SS, Lakhani HV, Edwards CE, Sodhi K. Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis. Int J Mol Sci 2020;21:E4737. [PMID: 32635162 DOI: 10.3390/ijms21134737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
441 Xu L, Jing M, Yang L, Jin L, Gong P, Lu J, Lin H, Wang J, Cao Q, Jiang Y. The Alisma and Rhizoma decoction abates nonalcoholic steatohepatitis-associated liver injuries in mice by modulating oxidative stress and autophagy. BMC Complement Altern Med 2019;19:92. [PMID: 31035991 DOI: 10.1186/s12906-019-2488-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
442 Liang H, Li Z, Ren Z, Jia Q, Guo L, Li S, Zhang H, Hu S, Zhu D, Shen D, Yu Z, Cheng K. Light-triggered NO-releasing nanoparticles for treating mice with liver fibrosis. Nano Res 2020;13:2197-202. [DOI: 10.1007/s12274-020-2833-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
443 Lin L, Gong H, Li R, Huang J, Cai M, Lan T, Huang W, Guo Y, Zhou Z, An Y, Chen Z, Liang L, Wang Y, Shuai X, Zhu K. Nanodrug with ROS and pH Dual-Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation. Adv Sci (Weinh) 2020;7:1903138. [PMID: 32274310 DOI: 10.1002/advs.201903138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
444 Tang G, Weng Z, Song J, Chen Y. Reversal effect of Jagged1 signaling inhibition on CCl4-induced hepatic fibrosis in rats. Oncotarget 2017;8:60778-88. [PMID: 28977825 DOI: 10.18632/oncotarget.18484] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
445 Schmidt-Arras D, Rose-John S. Regulation of Fibrotic Processes in the Liver by ADAM Proteases. Cells 2019;8:E1226. [PMID: 31601007 DOI: 10.3390/cells8101226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
446 Kawada N. Cytoglobin as a Marker of Hepatic Stellate Cell-derived Myofibroblasts. Front Physiol 2015;6:329. [PMID: 26617531 DOI: 10.3389/fphys.2015.00329] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
447 Shi H, Shi A, Dong L, Lu X, Wang Y, Zhao J, Dai F, Guo X. Chlorogenic acid protects against liver fibrosis in vivo and in vitro through inhibition of oxidative stress. Clinical Nutrition 2016;35:1366-73. [DOI: 10.1016/j.clnu.2016.03.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 15.4] [Reference Citation Analysis]
448 Liu T, Xu L, Wang C, Chen K, Xia Y, Li J, Li S, Wu L, Feng J, Xu S, Wang W, Lu X, Fan X, Mo W, Zhou Y, Zhao Y, Guo C. Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-β1/Smads pathway through shikonin. J Gastroenterol Hepatol 2019;34:263-76. [PMID: 29864192 DOI: 10.1111/jgh.14299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
449 Lucantoni F, Martínez-Cerezuela A, Gruevska A, Moragrega ÁB, Víctor VM, Esplugues JV, Blas-García A, Apostolova N. Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet? J Pathol 2021;254:216-28. [PMID: 33834482 DOI: 10.1002/path.5678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
450 Reungoat E, Grigorov B, Zoulim F, Pécheur EI. Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers (Basel) 2021;13:2270. [PMID: 34065048 DOI: 10.3390/cancers13092270] [Reference Citation Analysis]
451 Demetris AJ, Bellamy CO, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional Immune Anatomy of the Liver-As an Allograft. Am J Transplant. 2016;16:1653-1680. [PMID: 26848550 DOI: 10.1111/ajt.13749] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
452 Xia Y, Yu B, Ma C, Tu Y, Zhai L, Yang Y, Liu D, Liu Y, Wu H, Dan H, You P. Yu Gan Long reduces rat liver fibrosis by blocking TGF-β1/Smad pathway and modulating the immunity. Biomedicine & Pharmacotherapy 2018;106:1332-8. [DOI: 10.1016/j.biopha.2018.07.081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
453 Zayed RA, Omran D, Mokhtar DA, Zakaria Z, Ezzat S, Soliman MA, Mobarak L, El-Sweesy H, Emam G. Association of Toll-Like Receptor 3 and Toll-Like Receptor 9 Single Nucleotide Polymorphisms with Hepatitis C Virus Infection and Hepatic Fibrosis in Egyptian Patients. Am J Trop Med Hyg 2017;96:720-6. [PMID: 28093541 DOI: 10.4269/ajtmh.16-0644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
454 Crawford JM, Bioulac-sage P, Hytiroglou P. Structure, Function, and Responses to Injury. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 1-87. [DOI: 10.1016/b978-0-7020-6697-9.00001-7] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
455 Li XM, Peng JH, Sun ZL, Tian HJ, Duan XH, Liu L, Ma X, Feng Q, Liu P, Hu YY. Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways. Acta Pharmacol Sin 2016;37:783-93. [PMID: 27133300 DOI: 10.1038/aps.2016.35] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
456 Tariq S, Koloko BL, Malik A, Rehman S, Ijaz B, Shahid AA. Tectona grandis leaf extract ameliorates hepatic fibrosis: Modulation of TGF- β /Smad signaling pathway and upregulating MMP3/TIMP1 ratio. J Ethnopharmacol 2021;272:113938. [PMID: 33610708 DOI: 10.1016/j.jep.2021.113938] [Reference Citation Analysis]
457 Horowitz JM, Venkatesh SK, Ehman RL, Jhaveri K, Kamath P, Ohliger MA, Samir AE, Silva AC, Taouli B, Torbenson MS, Wells ML, Yeh B, Miller FH. Evaluation of hepatic fibrosis: A review from the society of abdominal radiology disease focus panel. Abdom Radiol (NY). 2017;42:2037-2053. [PMID: 28624924 DOI: 10.1007/s00261-017-1211-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
458 Aylon Y, Gershoni A, Rotkopf R, Biton IE, Porat Z, Koh AP, Sun X, Lee Y, Fiel MI, Hoshida Y, Friedman SL, Johnson RL, Oren M. The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev 2016;30:786-97. [PMID: 27013235 DOI: 10.1101/gad.274167.115] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
459 Gong H, Fan Z, Yi D, Chen J, Li Z, Guo R, Wang C, Fang W, Liu S. Histidine kinase NME1 and NME2 are involved in TGF-β1-induced HSC activation and CCl4-induced liver fibrosis. J Mol Histol 2020;51:573-81. [PMID: 32860079 DOI: 10.1007/s10735-020-09906-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
460 Fausther M, Lavoie EG, Goree JR, Dranoff JA. An Elf2-like transcription factor acts as repressor of the mouse ecto-5'-nucleotidase gene expression in hepatic myofibroblasts. Purinergic Signal 2017;13:417-28. [PMID: 28667437 DOI: 10.1007/s11302-017-9570-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
461 Gao Y, Shi W, Yao H, Ai Y, Li R, Wang Z, Liu T, Dai W, Xiao X, Zhao J, Niu M, Bai Z. An Integrative Pharmacology Based Analysis of Refined Liuweiwuling Against Liver Injury: A Novel Component Combination and Hepaprotective Mechanism. Front Pharmacol 2021;12:747010. [PMID: 34630116 DOI: 10.3389/fphar.2021.747010] [Reference Citation Analysis]
462 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]